cirazoline profile

cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2765
CHEMBL ID	13852
CHEBI ID	92950
SCHEMBL ID	126496
MeSH ID	M0062711

Synonym
BRD-K54142781-001-02-1
gtpl515
ld-3098
cirazolina [inn-spanish]
cirazoline [inn]
cirazolinum [inn-latin]
1h-imidazole, 2-((2-cyclopropylphenoxy)methyl)-4,5-dihydro-
2-((o-cyclopropylphenoxy)methyl)-2-imidazoline
LOPAC0_000354
NCGC00015196-01
BIO1_000412
tocris-0888
BIO2_000786
lopac-c-223
NCGC00024847-01
BIO2_000306
BIO1_000901
BIO1_001390
BSPBIO_001586
cirazoline
IDI1_034056
NCGC00024847-04
NCGC00024847-03
KBIOGR_000306
KBIO3_000612
KBIO2_005442
KBIO2_002874
KBIOSS_000306
KBIO2_000306
KBIO3_000611
NCGC00024847-05
NCGC00024847-02
HMS1989P08
HMS2089E21
NCGC00015196-07
L000800
CHEMBL13852 ,
HMS1361P08
HMS1791P08
59939-16-1
2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1h-imidazole
bdbm50027060
2-(2-cyclopropyl-phenoxymethyl)-4,5-dihydro-1h-imidazole (cirazoline)
2-(2-cyclopropyl-phenoxymethyl)-4,5-dihydro-1h-imidazole
NCGC00015196-04
dtxsid4045131 ,
cas-59939-16-1
dtxcid2025131
tox21_110095
CCG-204449
NCGC00015196-06
NCGC00015196-02
NCGC00015196-05
NCGC00015196-03
NCGC00015196-08
qk318gvy3y ,
cirazolinum
cirazolina
unii-qk318gvy3y
FT-0602943
SCHEMBL126496
tox21_110095_1
NCGC00015196-09
HMS3402P08
DB09202
CHEBI:92950
Q5121338
BRD-K54142781-003-08-4
BRD-K54142781-003-02-7
SDCCGSBI-0050342.P002
NCGC00015196-13
1h-imidazole, 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-

Excerpt	Reference
"Cirazoline was found to be a full agonist at alpha-1 receptors having an ED50, dissociation constant (KA) and relative efficacy similar to that of (-)-norepinephrine."	( Ruffolo, RR; Waddell, JE, 1982)

Excerpt	Reference
"Cirazoline has additional high affinity for imidazoline receptors and has good brain penetrance when administered systemically."	( Arnsten, AF; Jentsch, JD, 1997)

Excerpt	Reference
"Cirazoline did not produce a significant depolarisation in blood vessels of either normotensive or hypertensive rats."	( Bieger, D; Duggan, JA; Tabrizchi, R, 2004)

Class	Description
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	50.1187	0.0032	45.4673	12,589.2998	AID2517
Chain A, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID886
Chain B, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID886
acetylcholinesterase	Homo sapiens (human)	Potency	27.5404	0.0025	41.7960	15,848.9004	AID1347395
GALC protein	Homo sapiens (human)	Potency	0.6310	28.1838	28.1838	28.1838	AID1159614
TDP1 protein	Homo sapiens (human)	Potency	30.3001	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.9439	0.0007	14.5928	83.7951	AID1259392
Thrombopoietin	Homo sapiens (human)	Potency	25.1189	0.0251	7.3048	31.6228	AID917; AID918
AR protein	Homo sapiens (human)	Potency	7.4978	0.0002	21.2231	8,912.5098	AID1259243; AID1259247
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	39.8107	0.0013	18.0743	39.8107	AID926
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	1.8888	0.5318	15.4358	37.6858	AID504845
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	2.7202	0.0015	30.6073	15,848.9004	AID1224841; AID1259401
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	23.8911	0.0002	29.3054	16,493.5996	AID743075
cytochrome P450 2D6	Homo sapiens (human)	Potency	4.3649	0.0010	8.3798	61.1304	AID1645840
arylsulfatase A	Homo sapiens (human)	Potency	0.0953	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	33.5875	0.0355	20.9770	89.1251	AID504332
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	14.4409	0.0016	28.0151	77.1139	AID1224843; AID1224895; AID1259393
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	15.0654	0.0020	7.5337	39.8107	AID891
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	0.0013	0.0025	5.8400	31.6228	AID899
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	36.4261	0.0100	39.5371	1,122.0200	AID1469; AID1479
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	12.9244	0.0010	6.0009	35.4813	AID943; AID944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0347	0.0001	0.5326	10.0000	AID772375
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.0589	0.0001	0.8074	10.0000	AID443916; AID772379
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.5248	0.0002	0.7257	10.0000	AID443915; AID772378
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.5495	0.0003	0.4834	10.0000	AID443913; AID772377
Nischarin	Homo sapiens (human)	Ki	0.0990	0.0042	0.2192	3.8019	AID342861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-2B adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0005	1.3644	6.7100	AID443912; AID772381
Alpha-2C adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.3981	0.0005	0.5541	6.7100	AID443911; AID772380
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0378	0.0054	3.2510	20.9400	AID36629; AID37345
Alpha-1D adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.1259	0.0015	1.7227	5.6000	AID32972; AID35390; AID35445; AID35453
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0126	0.0126	0.0379	0.0631	AID36629
5-hydroxytryptamine receptor 1D	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0126	0.0013	0.0388	0.0970	AID36629
5-hydroxytryptamine receptor 1F	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0126	0.0126	0.0319	0.0631	AID36629
Alpha-1A adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0126	0.0001	0.5098	7.1000	AID32967; AID35381; AID36626; AID36629
Alpha-1B adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0631	0.0001	1.3010	5.6000	AID32970; AID35384; AID37345; AID37350
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-1D adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1D adrenergic receptor	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1B adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of cardiac muscle contraction	Alpha-1B adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1B adrenergic receptor	Homo sapiens (human)
apoptotic process	Nischarin	Homo sapiens (human)
Rac protein signal transduction	Nischarin	Homo sapiens (human)
actin cytoskeleton organization	Nischarin	Homo sapiens (human)
negative regulation of cell migration	Nischarin	Homo sapiens (human)
outer dynein arm assembly	Nischarin	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
integrin binding	Nischarin	Homo sapiens (human)
protein binding	Nischarin	Homo sapiens (human)
phosphatidylinositol binding	Nischarin	Homo sapiens (human)
identical protein binding	Nischarin	Homo sapiens (human)
dynein heavy chain binding	Nischarin	Homo sapiens (human)
alpha-tubulin binding	Nischarin	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
nucleoplasm	Nischarin	Homo sapiens (human)
early endosome	Nischarin	Homo sapiens (human)
cytosol	Nischarin	Homo sapiens (human)
plasma membrane	Nischarin	Homo sapiens (human)
microtubule cytoskeleton	Nischarin	Homo sapiens (human)
membrane	Nischarin	Homo sapiens (human)
intracellular membrane-bounded organelle	Nischarin	Homo sapiens (human)
intercellular bridge	Nischarin	Homo sapiens (human)
recycling endosome	Nischarin	Homo sapiens (human)
cytoplasm	Nischarin	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID37350	In vitro activation of human Alpha-1B receptor expressed in rat-1 fibroblasts via calcium mobilization through the Gq coupled PLC pathway as functional assay	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.
AID35384	Activation of human alpha-1B adrenergic receptors expressed in rat-1 fibroblasts	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID443915	Displacement of [3H]RX821002 from human alpha2B adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID772382	Antagonist activity at human alpha2A AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID443912	Agonist activity at human alpha2B adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID772375	Binding affinity at human 5HT1A receptor	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID772379	Binding affinity at human alpha2A AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID35331	Ability to activate human alpha-1D receptor expressed in rat-1 fibroblasts as calcium mobilization through Gq coupled PLC pathway relative to phenylephrine response	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID772377	Binding affinity at human alpha2C AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID23715	Apparent partion coefficient of compound was evaluated in octanol/buffer at pH of 7.4 at 37 degree Centigrade	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID197169	Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID342861	Displacement of [125I]PIC from human imidazoline receptor 1 in human platelets analyzed under norepinephrine mask of alpha 2AR	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	QSAR study of imidazoline antihypertensive drugs.
AID443905	Intrinsic activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry relative to noradrenaline	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID32971	Tested for efficacy against alpha 1D-adrenoceptor in human expressed as phenylephrine response at the dose of 40 uM	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID180899	The dose required to increase diastolic blood pressure by 50 mmHg in pithed rats after intravenous administration	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	N-substituted imidazolines and ethylenediamines and their action on alpha- and beta-adrenergic receptors.
AID36629	In vitro activation of human alpha-1A receptor expressed in rat-1 fibroblasts via calcium mobilization through the Gq coupled PLC pathway as functional assay	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.
AID174088	Tested for alpha1 adrenoceptor-Mediated Pressor Response in Pithed Rats; Dose ratio subsequent administration of antagonist (Prazosin) intravenously at a dose of 0.1 mg/kg	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	N-substituted imidazolines and ethylenediamines and their action on alpha- and beta-adrenergic receptors.
AID35453	In vitro activation of human alpha-1D receptor expressed in rat-1 fibroblasts via calcium using mobilization through the Gq coupled PLC pathway as functional assay	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.
AID32967	Agonist potency against cloned human alpha 1A adrenoceptor expressed in rat-1 fibroblasts.	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID772372	Binding affinity to I2 imidazoline binding site in rat brain membrane	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID35381	Activation of human alpha-1A adrenergic receptor expressed in rat-1 fibroblasts	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID342863	Selectivity ratio of pKi for human imidazoline receptor 1 to pKi for human alpha2 adrenoceptors	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	QSAR study of imidazoline antihypertensive drugs.
AID772378	Binding affinity at human alpha2B AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID32970	Potency against cloned human alpha 1B adrenoceptor expressed in rat-1 fibroblasts.	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID772381	Agonist activity at human alpha2B AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID443913	Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID772380	Agonist activity at human alpha2C AR	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID443910	Antagonist activity at human alpha2A adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID36626	Activation of recombinant human adrenergic,alpha-1A receptor expressed in rat-1 fibroblasts determined via calcium mobilization through Gq coupled PLC pathway	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID37345	Activation of recombinant human adrenergic, alpha-1B receptor expressed in rat-1 fibroblasts determined via calcium mobilization through Gq coupled PLC pathway	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID36726	Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.2 nM) to rat isolated brain membranes by 50% was reported; 8.9*10e-7	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID36620	Ability to activate cloned human alpha-1A receptor expressed in rat-1 fibroblasts via calcium mobilization through Gq coupled PLC pathway expressed as percent of phenylephrine (40 uM) response	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID443911	Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID174091	Tested for alpha-2 adrenoceptor-Mediated PressorResponse in Pithed Rats; Dose ratio by subsequent administration of antagonist (yohimbine) intravenously at a dose of 1 mg/kg	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	N-substituted imidazolines and ethylenediamines and their action on alpha- and beta-adrenergic receptors.
AID35383	Activation of human alpha-1B-adrenoceptor receptors expressed in rat-1 fibroblasts as percent maximal effect relative to phenylephrine	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID35390	Activation of human Alpha-1D adrenergic receptors expressed in rat-1 fibroblasts	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID342860	Displacement of [125I]PIC from human alpha2 adrenoceptors expressed in CHO cells	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	QSAR study of imidazoline antihypertensive drugs.
AID443916	Displacement of [3H]RX821002 from human alpha2A adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID36793	Binding affinity against Alpha-2 adrenergic receptor is the ability to inhibit the specific [3H]-clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was reported; 5.9*10e-8	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID772358	Agonist activity at human 5HT1A receptor assessed as intrinsic activity	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID91715	Binding affinity for imidazoline receptor I-2 in rabbit kidney homogenate (relative to [3H]-Idazoxan radioligand)	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology.
AID35445	Activation of recombinant human adrenergic, alpha-1D receptor expressed in rat-1 fibroblasts assayed via calcium mobilization through Gq coupled PLC pathway	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID32972	Potency against cloned human alpha 1D-adrenoceptor expressed in rat-1 fibroblasts.	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID37338	Activation of human alpha-1B receptor expressed in rat-1 fibroblasts by calcium mobilization of Gq coupled PLC as percent phenylephrine (40 uM) response	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
AID35380	Activation of human alpha-1A adrenergic receptor expressed in rat-1 fibroblasts; expressed as a percent of the maximal effect of the phenylephrine	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID235537	The selectivity was evaluated against alpha 1 and alpha 2 adrenoceptor	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	N-substituted imidazolines and ethylenediamines and their action on alpha- and beta-adrenergic receptors.
AID443906	Intrinsic activity at human alpha2B adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry relative to noradrenaline	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?
AID35389	Activation of human alpha-1D-adrenoceptor receptor expressed in rat-1 fibroblasts relative to phenylephrine	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.
AID32969	Efficacy against alpha 1B-adrenoceptor in human expressed as phenylephrine response at the dose of 40 uM.	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID32966	Efficacy against alpha 1A adrenoceptor in human expressed as phenylephrine response at the dose of 40 uM	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.
AID36312	Selective Alpha-1 adrenergic receptor agonistic activity;no data	2003	Journal of medicinal chemistry, May-08, Volume: 46, Issue:10	Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives.
AID1345920	Rat alpha1D-adrenoceptor (Adrenoceptors)	1994	Molecular pharmacology, Nov, Volume: 46, Issue:5	Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	62 (28.57)	18.7374
1990's	68 (31.34)	18.2507
2000's	56 (25.81)	29.6817
2010's	24 (11.06)	24.3611
2020's	7 (3.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	226 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
7-hydroxy-2-n,n-dipropylaminotetralin	[no description available]	medium	1	tetralins
brimonidine	[no description available]	medium	1	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
clonidine	[no description available]	medium	65	clonidine; imidazoline
mianserin	[no description available]	medium	1	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
naphazoline	[no description available]	medium	4	naphthalenes
oxymetazoline	[no description available]	medium	10	carboxamidine; imidazolines; phenols	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
prazosin	[no description available]	medium	38	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
talipexole	[no description available]	medium	13	azepine
tetrahydrozoline	[no description available]	medium	1	carboxamidine; imidazolines	nasal decongestant; sympathomimetic agent
tolazoline	[no description available]	medium	4	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent
tramazoline	[no description available]	medium	1	tetralins
xylazine	[no description available]	medium	6	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
xylometazoline	[no description available]	medium	2	alkylbenzene
phentolamine	[no description available]	medium	4	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
piperoxan	[no description available]	medium	2
phenylephrine	[no description available]	medium	39	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
methoxamine	[no description available]	medium	15	amphetamines	alpha-adrenergic agonist; antihypotensive agent
azapetine	[no description available]	medium	1	benzazepine
yohimbine	[no description available]	medium	22	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
dihydroergotamine	[no description available]	medium	1	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
amidephrine	[no description available]	medium	6	sulfonamide
lofexidine	[no description available]	medium	1	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent
5,6-dihydroxy-2-dimethylaminotetralin	[no description available]	medium	2	tetralins
tiamenidine	[no description available]	medium	2	organochlorine compound
corynanthine	[no description available]	medium	1	yohimban alkaloid
st 587	[no description available]	medium	20
indanidine	[no description available]	medium	9
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin	[no description available]	medium	1
(3,4-dihydroxyphenylamino)-2-imidazoline	[no description available]	medium	2
2-(n,n-dipropyl)amino-6,7-dihydroxytetralin	[no description available]	medium	1
5-hydroxy-2-n,n-dipropylaminotetralin	[no description available]	medium	1
rauwolscine	[no description available]	medium	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate
guanabenz	[no description available]	medium	8	dichlorobenzene
clozapine	[no description available]	medium	2	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
6-fluoronorepinephrine	[no description available]	medium	2	catechols
sk&f 89748	[no description available]	medium	4
corbadrine	[no description available]	medium	1	catecholamine	alpha-adrenergic agonist; nasal decongestant; vasoconstrictor agent
bu 224	[no description available]	medium	1	quinolines
2-phenyl-2-imidazoline	[no description available]	medium	1
idazoxan	[no description available]	medium	24	benzodioxine; imidazolines	alpha-adrenergic antagonist
2-phenylimidazole	[no description available]	medium	1
fenoxazoline	[no description available]	medium	1	alkylbenzene
2-(2-benzofuranyl)-2-imidazoline	[no description available]	medium	4	benzofurans
tracizoline	[no description available]	medium	3
2-(2-fluoro-5-methylphenyl)-4,5-dihydro-1h-imidazole	[no description available]	medium	1
agmatine	[no description available]	medium	3	guanidines; primary amino compound	Escherichia coli metabolite; mouse metabolite
moxonidine	[no description available]	medium	4	organohalogen compound; pyrimidines
rilmenidine	[no description available]	medium	8	isourea
efaroxan	[no description available]	medium	4	1-benzofurans
guanfacine	[no description available]	medium	3	acetamides
4-iodoclonidine	[no description available]	medium	2
tizanidine	[no description available]	medium	1	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
4-chloro-2-(2-imidazolin-2-ylamino)isoindoline	[no description available]	medium	1
8-hydroxy-2-(di-n-propylamino)tetralin	[no description available]	medium	2	phenols; tertiary amino compound; tetralins	serotonergic antagonist
fluoxetine	[no description available]	medium	1	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
2-(1-(2-allylphenoxy)ethyl)-4,5-dihydro-1h-imidazole	[no description available]	medium	1
atomoxetine hydrochloride	[no description available]	medium	1	hydrochloride	adrenergic uptake inhibitor; antidepressant
atipamezole	[no description available]	medium	1
propranolol	[no description available]	medium	8	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
cl 316243	[no description available]	medium	1
rtki cpd	[no description available]	medium	1
quinazolines	[no description available]	medium	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
isoproterenol	[no description available]	medium	15	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
xamoterol	[no description available]	medium	1	morpholines
ici 118551	[no description available]	medium	4	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
brl 37344	[no description available]	medium	2	monocarboxylic acid
chlorine	[no description available]	medium	5	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
sr 59230a	[no description available]	medium	1
azepexole	[no description available]	medium	14
n-methylaspartate	[no description available]	medium	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
morphine	[no description available]	medium	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
reboxetine	[no description available]	medium	1	aromatic ether
citalopram	[no description available]	medium	1	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
guanosine 5'-o-(2-thiodiphosphate)	[no description available]	medium	1	nucleoside diphosphate analogue
guanosine diphosphate	[no description available]	medium	1	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
benzofurans	[no description available]	medium	8
ly 320135	[no description available]	medium	1	benzofurans
a 61603	[no description available]	medium	2	tetralins
thapsigargin	[no description available]	medium	1	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
tubocurarine	[no description available]	medium	1	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
iberiotoxin	[no description available]	medium	1
charybdotoxin	[no description available]	medium	2
niflumic acid	[no description available]	medium	3	aromatic carboxylic acid; pyridines
dibenzylchlorethamine	[no description available]	medium	1
phenoxybenzamine	[no description available]	medium	17	aromatic amine
szl 49	[no description available]	medium	3
brl 44408	[no description available]	medium	2
amiloride	[no description available]	medium	4	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
8-epi-prostaglandin f2alpha	[no description available]	medium	1	F2-isoprostane	biomarker; bronchoconstrictor agent; vasoconstrictor agent
ng-nitroarginine methyl ester	[no description available]	medium	9	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
desoxycorticosterone	[no description available]	medium	2	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
indomethacin	[no description available]	medium	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
dinoprost	[no description available]	medium	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
1-ethyl-2-benzimidazolinone	[no description available]	medium	1	imidazoles
brimonidine tartrate	[no description available]	medium	23
quinoxalines	[no description available]	medium	24	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
methacholine chloride	[no description available]	medium	1	quaternary ammonium salt
cyclic gmp	[no description available]	medium	2	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
propionic acid	[no description available]	medium	1	saturated fatty acid; short-chain fatty acid	antifungal drug
harmine	[no description available]	medium	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
harman	[no description available]	medium	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
neurotensin	[no description available]	medium	1	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
4-iodo-2,5-dimethoxyphenylisopropylamine	[no description available]	medium	1	amphetamines; dimethoxybenzene; organoiodine compound
benoxathian	[no description available]	medium	4
fg 7142	[no description available]	medium	1	beta-carbolines
tetradecanoylphorbol acetate	[no description available]	medium	3	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
lithium carbonate	[no description available]	medium	1	carbonate salt; lithium salt	antimanic drug
chelerythrine	[no description available]	medium	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
valproic acid	[no description available]	medium	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
nitrites	[no description available]	medium	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
nitrates	[no description available]	medium	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
triiodothyronine	[no description available]	medium	1	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
5-methylurapidil	[no description available]	medium	3
cgp 12177	[no description available]	medium	3	aromatic ether; benzimidazoles; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
hp 873	[no description available]	medium	1	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
apomorphine	[no description available]	medium	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
piperidines	[no description available]	medium	3
phencyclidine	[no description available]	medium	2	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
isoxazoles	[no description available]	medium	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
alprenolol	[no description available]	medium	2	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
sk&f 86466	[no description available]	medium	2	benzazepine
staurosporine	[no description available]	medium	2	ammonium ion derivative
atrial natriuretic factor	[no description available]	medium	1	polypeptide
ibotenic acid	[no description available]	medium	1	non-proteinogenic alpha-amino acid	neurotoxin
phenobarbital	[no description available]	medium	2	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
nifedipine	[no description available]	medium	22	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
potassium chloride	[no description available]	medium	3	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
verapamil	[no description available]	medium	5	aromatic ether; nitrile; polyether; tertiary amino compound
ifenprodil	[no description available]	medium	1	piperidines
diltiazem	[no description available]	medium	4	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
tyramine	[no description available]	medium	2	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
angiotensin ii	[no description available]	medium	6	amino acid zwitterion; angiotensin II	human metabolite
proline	[no description available]	medium	2	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
enalapril	[no description available]	medium	2	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
captopril	[no description available]	medium	5	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
dobutamine	[no description available]	medium	2	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
pentobarbital	[no description available]	medium	2	barbiturates	GABAA receptor agonist
glycerol	[no description available]	medium	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
2-naphthol	[no description available]	medium	1	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
wb 4101	[no description available]	medium	4	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
raubasine	[no description available]	medium	1	yohimban alkaloid
guanoxabenz	[no description available]	medium	1
thiophenes	[no description available]	medium	2	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
darodipine	[no description available]	medium	1
nordefrin	[no description available]	medium	2	catecholamine
s 9871	[no description available]	medium	1
cobalt	[no description available]	medium	1	cobalt group element atom; metal allergen	micronutrient
phenethylamine	[no description available]	medium	1	alkaloid; aralkylamine; phenylethylamine	Escherichia coli metabolite; human metabolite; mouse metabolite
aldosterone	[no description available]	medium	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
losartan	[no description available]	medium	1	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
rx 821002	[no description available]	medium	3	benzodioxine; cyclic ketal; imidazolines	alpha-adrenergic antagonist
diazoxide	[no description available]	medium	1	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
clorgyline	[no description available]	medium	1	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
oxazoles	[no description available]	medium	6	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
n-vinyl-2-pyrrolidinone	[no description available]	medium	1	pyrrolidin-2-ones
arginine	[no description available]	medium	3	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
2-(4'-isothiocyanatobenzyl)imidazoline	[no description available]	medium	1
eedq	[no description available]	medium	1
bay-k-8644	[no description available]	medium	5	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
propylthiouracil	[no description available]	medium	1	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
thyroxine	[no description available]	medium	1	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
mivazerol	[no description available]	medium	1
sq-11725	[no description available]	medium	1
cocaine	[no description available]	medium	1	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
betaxolol	[no description available]	medium	1	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
tertatolol	[no description available]	medium	1	thiochromane
metizoline	[no description available]	medium	1	1-benzothiophenes
phenelzine	[no description available]	medium	1	primary amine
serine	[no description available]	medium	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ml 9	[no description available]	medium	1
chlorethylclonidine	[no description available]	medium	4
isothiocyanic acid	[no description available]	medium	1	hydracid; one-carbon compound
s 16924	[no description available]	medium	1
quetiapine fumarate	[no description available]	medium	1	fumarate salt
raclopride	[no description available]	medium	1	salicylamides
nicergoline	[no description available]	medium	1	organic heterotetracyclic compound; organonitrogen heterocyclic compound
antazoline	[no description available]	medium	1	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
dizocilpine maleate	[no description available]	medium	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
imidazole	[no description available]	medium	2	imidazole
glutamic acid	[no description available]	medium	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
nitroarginine	[no description available]	medium	3	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
ibuprofen	[no description available]	medium	2	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
tetrabutylammonium	[no description available]	medium	2	quaternary ammonium ion
indoramin	[no description available]	medium	1	tryptamines
bmy 7378	[no description available]	medium	2
4-aminopyridine	[no description available]	medium	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
ouabain	[no description available]	medium	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
glyburide	[no description available]	medium	1	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
oxadiazoles	[no description available]	medium	2
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	[no description available]	medium	1	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor
am 404	[no description available]	medium	1	anilide
mk 473	[no description available]	medium	2
mibefradil	[no description available]	medium	2	tetralins	T-type calcium channel blocker
colforsin	[no description available]	medium	4	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
calcimycin	[no description available]	medium	1	benzoxazole
dexniguldipine	[no description available]	medium	1	diarylmethane
phenylalanine	[no description available]	medium	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
dihydropyridines	[no description available]	medium	2
flesinoxan	[no description available]	medium	1
bicuculline	[no description available]	medium	1	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
tetrodotoxin	[no description available]	medium	1	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	[no description available]	medium	1	alkylbenzene; ring assembly
anandamide	[no description available]	medium	1	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
veratridine	[no description available]	medium	1
cyclohexanol	[no description available]	medium	1	cyclohexanols; secondary alcohol	solvent
albuterol	[no description available]	medium	1	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
pituitrin	[no description available]	medium	2
bucladesine	[no description available]	medium	2	3',5'-cyclic purine nucleotide
thymidine	[no description available]	medium	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
8-bromo cyclic adenosine monophosphate	[no description available]	medium	1	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
amphetamine	[no description available]	medium	1	primary amine
phenylpropanolamine	[no description available]	medium	1	amphetamines; phenethylamine alkaloid	plant metabolite
carvedilol	[no description available]	medium	2	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
medetomidine	[no description available]	medium	1	imidazoles
guanethidine	[no description available]	medium	1	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
hydrogen	[no description available]	medium	1	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
urapidil	[no description available]	medium	1	piperazines
pindolol	[no description available]	medium	1	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
1-methyl-3-isobutylxanthine	[no description available]	medium	1	3-isobutyl-1-methylxanthine
ethylisopropylamiloride	[no description available]	medium	1	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
cimetidine	[no description available]	medium	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
bimakalim	[no description available]	medium	1
pyrroles	[no description available]	medium	2	pyrrole; secondary amine
cromakalim	[no description available]	medium	2
nitrendipine	[no description available]	medium	2	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
6-ketoprostaglandin f1 alpha	[no description available]	medium	1	prostaglandins Falpha	human metabolite; mouse metabolite
perindopril	[no description available]	medium	1	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
angiotensin i	[no description available]	medium	1	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent
valinomycin	[no description available]	medium	1	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein	[no description available]	medium	1
erythrosine	[no description available]	medium	1
sotalol	[no description available]	medium	1	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
reserpine	[no description available]	medium	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
lanthanum	[no description available]	medium	1	f-block element atom; lanthanoid atom; scandium group element atom
isradipine	[no description available]	medium	1	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
benextramine	[no description available]	medium	2
cystamine	[no description available]	medium	2	organic disulfide; primary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
dimethyl sulfoxide	[no description available]	medium	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
tiapamil hydrochloride	[no description available]	medium	1
quinacrine	[no description available]	low	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
vanilmandelic acid	[no description available]	low	0	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite
4-(2,4-dichlorophenoxy)butyric acid	[no description available]	low	0	aromatic ether; monocarboxylic acid; organochlorine compound	agrochemical; phenoxy herbicide; synthetic auxin
win 52035	[no description available]	low	0	aromatic ether
win 52084	[no description available]	low	0	aromatic ether
5-(nonyloxy)tryptamine	[no description available]	low	0	aromatic ether; primary amino compound; tryptamines	serotonergic agonist
methylbufotenin	[no description available]	low	0	aromatic ether; tertiary amino compound; tryptamine alkaloid	hallucinogen; plant metabolite
5-methoxytryptamine	[no description available]	low	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
ro 48-8071	[no description available]	low	0	aromatic ether; aromatic ketone; bromobenzenes; monofluorobenzenes; olefinic compound; tertiary amino compound	antineoplastic agent; EC 5.4.99.7 (lanosterol synthase) inhibitor
rtki cpd	[no description available]	low	0	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
amsacrine	[no description available]	low	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
aristolochic acid i	[no description available]	low	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one	[no description available]	low	0	aromatic ether; benzoxazine; cyclic hydroxamic acid; lactol	allelochemical; plant metabolite
bufetolol	[no description available]	low	0	aromatic ether
bufexamac	[no description available]	low	0	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bunitrolol	[no description available]	low	0	aromatic ether
bupranolol	[no description available]	low	0	aromatic ether
ciglitazone	[no description available]	low	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
clofibrate	[no description available]	low	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofibric acid	[no description available]	low	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
colchicine, (+-)-isomer	[no description available]	low	0	acetamides; alkaloid; aromatic ether; carbotricyclic compound	microtubule-destabilising agent; plant metabolite
croconazole	[no description available]	low	0	aromatic ether; conazole antifungal drug; imidazole antifungal drug; monochlorobenzenes
cypermethrin	[no description available]	low	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound	agrochemical; molluscicide; pyrethroid ester acaricide; pyrethroid ester insecticide
racemethorphan	[no description available]	low	0	aromatic ether; morphinane alkaloid; morphinane-like compound; organic heterotetracyclic compound
dibucaine	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
dilacor xr	[no description available]	low	0	acetate ester; aromatic ether; benzothiazepine; lactam; tertiary amino compound
domiphen	[no description available]	low	0	aromatic ether
donepezil	[no description available]	low	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
epirizole	[no description available]	low	0	aromatic ether
ethacrynic acid	[no description available]	low	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethoxyquin	[no description available]	low	0	aromatic ether; quinolines	antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator
ethoxzolamide	[no description available]	low	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2-hexyloxybenzamide	[no description available]	low	0	aromatic ether; benzamides	antifungal agent
carbonyl cyanide p-trifluoromethoxyphenylhydrazone	[no description available]	low	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
fenofibrate	[no description available]	low	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenvalerate	[no description available]	low	0	aromatic ether; carboxylic ester; monochlorobenzenes	pyrethroid ester acaricide; pyrethroid ester insecticide
flecainide	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
gallamine triethiodide	[no description available]	low	0	aromatic ether
gemfibrozil	[no description available]	low	0	aromatic ether	antilipemic drug
haloprogin	[no description available]	low	0	aromatic ether
ipriflavone	[no description available]	low	0	aromatic ether; isoflavones	bone density conservation agent
ly 171883	[no description available]	low	0	acetophenones; aromatic ether; phenols; tetrazoles	anti-asthmatic drug; leukotriene antagonist
mephenesin	[no description available]	low	0	aromatic ether; glycerol ether
methocarbamol	[no description available]	low	0	aromatic ether; carbamate ester; secondary alcohol
methoctramine	[no description available]	low	0	aromatic ether; tetramine	muscarinic antagonist
methoxsalen	[no description available]	low	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
metoprolol	[no description available]	low	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
mexiletine	[no description available]	low	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midodrine	[no description available]	low	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
nefazodone	[no description available]	low	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nimesulide	[no description available]	low	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nisoxetine	[no description available]	low	0	aromatic ether; secondary amino compound	adrenergic uptake inhibitor; antidepressant
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[no description available]	low	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
omeprazole	[no description available]	low	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
oxprenolol	[no description available]	low	0	aromatic ether
pantoprazole	[no description available]	low	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
pd 153035	[no description available]	low	0	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pentamidine	[no description available]	low	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
phenacetin	[no description available]	low	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
pioglitazone	[no description available]	low	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piretanide	[no description available]	low	0	aromatic ether
pramoxine	[no description available]	low	0	aromatic ether; morpholines	local anaesthetic
primaquine	[no description available]	low	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
proglumetacin	[no description available]	low	0	aromatic ether; benzamides; carboxylic ester; monochlorobenzenes; N-acylindole; N-alkylpiperazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
propoxur	[no description available]	low	0	aromatic ether; carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
pyrilamine	[no description available]	low	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
sulfadimethoxine	[no description available]	low	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
tetrahydropapaverine	[no description available]	low	0	aromatic ether; benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; polyether; secondary amino compound
tilorone	[no description available]	low	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
ultram	[no description available]	low	0	aromatic ether; tertiary alcohol; tertiary amino compound
triclosan	[no description available]	low	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
viloxazine	[no description available]	low	0	aromatic ether
3,3',5-triiodothyropropionic acid	[no description available]	low	0	aromatic ether
methacetin	[no description available]	low	0	acetamides; aromatic ether
mestranol	[no description available]	low	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
visnagin	[no description available]	low	0	aromatic ether; furanochromone; polyketide	anti-inflammatory agent; antihypertensive agent; EC 1.1.1.37 (malate dehydrogenase) inhibitor; phytotoxin; plant metabolite; vasodilator agent
2-tert-butyl-4-hydroxyanisole	[no description available]	low	0	aromatic ether; phenols
mecoprop	[no description available]	low	0	aromatic ether; monocarboxylic acid; monochlorobenzenes
phenetidine	[no description available]	low	0	aromatic ether; substituted aniline
2-methyl-4-chlorophenoxy gamma-butyric acid	[no description available]	low	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; xenobiotic
4-bromophenyl phenyl ether	[no description available]	low	0	aromatic ether; organobromine compound
di-(4-aminophenyl)ether	[no description available]	low	0	aromatic ether
phenyl ether	[no description available]	low	0	aromatic ether	plant metabolite
diglycidyl resorcinol ether	[no description available]	low	0	aromatic ether
phenetole	[no description available]	low	0	aromatic ether
scoparone	[no description available]	low	0	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite
dimethoxyphenylethylamine	[no description available]	low	0	alkaloid; aromatic ether; phenylethylamine	allergen; plant metabolite
dichlorprop	[no description available]	low	0	aromatic ether; dichlorobenzene; monocarboxylic acid
3-tert-butyl-4-hydroxyanisole	[no description available]	low	0	aromatic ether; phenols	antioxidant; human xenobiotic metabolite
ethyl vanillin	[no description available]	low	0	aromatic ether; benzaldehydes; phenols	antioxidant; flavouring agent
benzethonium chloride	[no description available]	low	0	aromatic ether; chloride salt; quaternary ammonium salt	antibacterial agent; antifungal agent; antiseptic drug; antiviral agent; disinfectant
peucedanin	[no description available]	low	0	aromatic ether; furanocoumarin; lactone	plant metabolite
phenetidine	[no description available]	low	0	aromatic ether; primary amino compound; substituted aniline	drug metabolite
6-methoxybenzoxazolinone	[no description available]	low	0	aromatic ether; benzoxazole	antibacterial agent; anticonvulsant; antifungal agent; muscle relaxant; plant metabolite
3-anisidine	[no description available]	low	0	aromatic ether; substituted aniline
domiphen bromide	[no description available]	low	0	aromatic ether
dibrompropamidine	[no description available]	low	0	aromatic ether
4-Ethoxyphenol	[no description available]	low	0	aromatic ether; phenols
bulbocapnine	[no description available]	low	0	aporphine alkaloid; aromatic ether; oxacycle; phenols	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; EC 1.4.3.22 (diamine oxidase) inhibitor; plant metabolite
benzydamine	[no description available]	low	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
xylocholine	[no description available]	low	0	aromatic ether
3-methoxycatechol	[no description available]	low	0	aromatic ether; catechols	G-protein-coupled receptor agonist
2-phenoxypropanoic acid	[no description available]	low	0	aromatic ether; carboxylic acid
6-methoxyquinoline	[no description available]	low	0	aromatic ether; quinolines
metaxalone	[no description available]	low	0	aromatic ether
heliamine	[no description available]	low	0	aromatic ether; diether; isoquinoline alkaloid; isoquinolines	plant metabolite
2,4,6-trichlorophenyl 4-nitrophenyl ether	[no description available]	low	0	aromatic ether; C-nitro compound; chlorobenzenes	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
etridiazol	[no description available]	low	0	aromatic ether; organochlorine compound; thiadiazole antifungal agent; thiadiazoles	antifungal agrochemical; nitrification inhibitor
toliprolol	[no description available]	low	0	aromatic ether
5-methoxyindoleacetic acid	[no description available]	low	0	aromatic ether; indole-3-acetic acids	antibacterial agent; Brassica napus metabolite; carcinogenic agent; human urinary metabolite; marine xenobiotic metabolite; rat metabolite
iproclozide	[no description available]	low	0	aromatic ether
phenoxyacetic acid	[no description available]	low	0	aromatic ether; monocarboxylic acid	allergen; Aspergillus metabolite; human xenobiotic metabolite; plant growth retardant
nafenopin	[no description available]	low	0	aromatic ether; monocarboxylic acid
methyl vanillate	[no description available]	low	0	aromatic ether; benzoate ester; phenols	antioxidant; plant metabolite
5-methoxyindole-2-carboxylic acid	[no description available]	low	0	aromatic ether; indolecarboxylic acid	EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor; hypoglycemic agent; plant metabolite
2-isopropoxyphenol	[no description available]	low	0	aromatic ether; phenols
dehydroemetine	[no description available]	low	0	aromatic ether; isoquinolines; pyridoisoquinoline	antileishmanial agent; antimalarial; antiprotozoal drug
1,2-epoxy-3-(p-nitrophenoxy)propane	[no description available]	low	0	aromatic ether; C-nitro compound; epoxide
laurolitsine	[no description available]	low	0	aporphine alkaloid; aromatic ether; phenols	HIV-1 integrase inhibitor; metabolite
metocurine iodide	[no description available]	low	0	aromatic ether
ac 45594	[no description available]	low	0	aromatic ether
3-phenoxybenzylalcohol	[no description available]	low	0	aromatic ether; benzyl alcohols	marine xenobiotic metabolite
devrinol	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; naphthalenes
fluorodifen	[no description available]	low	0	aromatic ether
acridine half-mustard	[no description available]	low	0	aminoacridines; aromatic ether; organochlorine compound; secondary amino compound	mutagen
precocene i	[no description available]	low	0	aromatic ether; chromenes	plant metabolite; precocenes
oxadiazon	[no description available]	low	0	aromatic ether
alclofenac	[no description available]	low	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
phenylglycidyl ether	[no description available]	low	0	aromatic ether
phenoxyethanol	[no description available]	low	0	aromatic ether; glycol ether; primary alcohol	antiinfective agent; central nervous system depressant
metipranolol	[no description available]	low	0	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
silybin	[no description available]	low	0	aromatic ether; benzodioxine; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; hepatoprotective agent; plant metabolite
oxamethacin	[no description available]	low	0	aromatic ether; hydroxamic acid; N-acylindole; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
canadine	[no description available]	low	0	aromatic ether; berberine alkaloid; organic heteropentacyclic compound; oxacycle
7-ethoxycoumarin	[no description available]	low	0	aromatic ether; coumarins
medifoxamine	[no description available]	low	0	aromatic ether
chlormethoxynil	[no description available]	low	0	aromatic ether
climbazole	[no description available]	low	0	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
4-hexyloxyaniline	[no description available]	low	0	aromatic ether; substituted aniline
ticrynafen	[no description available]	low	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
2-(4-(2,4-dichlorophenoxy)phenoxy)propionic acid	[no description available]	low	0	aromatic ether; dichlorobenzene; diether; monocarboxylic acid
bezafibrate	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
oxyfluorofen	[no description available]	low	0	aromatic ether	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
triadimefon	[no description available]	low	0	aromatic ether; hemiaminal ether; ketone; monochlorobenzenes; triazoles
levobunolol	[no description available]	low	0	aromatic ether; cyclic ketone; propanolamine	antiglaucoma drug; beta-adrenergic antagonist
dichlorfop-methyl	[no description available]	low	0	aromatic ether; dichlorobenzene; diether; methyl ester
decamethrin	[no description available]	low	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
triadimenol	[no description available]	low	0	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
triclopyr	[no description available]	low	0	aromatic ether; chloropyridine; monocarboxylic acid	agrochemical; environmental contaminant; herbicide; xenobiotic
prenalterol	[no description available]	low	0	aromatic ether
st 1059	[no description available]	low	0	aromatic ether; primary amino compound; secondary alcohol	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
paroxetine	[no description available]	low	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
acifluorfen	[no description available]	low	0	aromatic ether; benzoic acids; C-nitro compound; monocarboxylic acid; organochlorine compound; organofluorine compound	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
bopindolol	[no description available]	low	0	aromatic ether; benzoate ester; methylindole; secondary amino compound
fenpropathrin, (+-)-isomer	[no description available]	low	0	aromatic ether; cyclopropanecarboxylate ester	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
triflumuron	[no description available]	low	0	aromatic ether; benzoylurea insecticide; monochlorobenzenes; organofluorine compound
flutolanil	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; benzamides; benzanilide fungicide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
fenoxaprop ethyl	[no description available]	low	0	aromatic ether
triclabendazole	[no description available]	low	0	aromatic ether
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid	[no description available]	low	0	aminopyridine; aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound	environmental contaminant; herbicide; xenobiotic
fluvalinate	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; nitrile; organochlorine acaricide; organochlorine insecticide; organofluorine acaricide; organofluorine insecticide	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
haloxyfop	[no description available]	low	0	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines
fluazifop-butyl	[no description available]	low	0	aromatic ether; carboxylic ester; organofluorine compound; pyridines
fomesafen	[no description available]	low	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-sulfonylcarboxamide; organofluorine compound; phenols	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
fenoxycarb	[no description available]	low	0	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
quizalofop-ethyl	[no description available]	low	0	aromatic ether; ethyl ester; organochlorine compound; quinoxaline derivative
cetamolol	[no description available]	low	0	aromatic ether
atomoxetine	[no description available]	low	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
methyl bensulfuron	[no description available]	low	0	aromatic ether; methyl ester; N-sulfonylurea; pyrimidines	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
itraconazole	[no description available]	low	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
loxtidine	[no description available]	low	0	aromatic ether; piperidines; primary alcohol; triazoles	H2-receptor antagonist
disoxaril	[no description available]	low	0	aromatic ether
chlorimuron ethyl	[no description available]	low	0	aromatic ether; ethyl ester; N-sulfonylurea; organochlorine pesticide; pyrimidines; sulfamoylbenzoate	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; proherbicide
tepoxalin	[no description available]	low	0	aromatic ether; hydroxamic acid; monochlorobenzenes; pyrazoles	antipyretic; apoptosis inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; immunomodulator; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
esmolol	[no description available]	low	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
pioglitazone hydrochloride	[no description available]	low	0	aromatic ether
aripiprazole	[no description available]	low	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
sulfametrole	[no description available]	low	0	aromatic ether; substituted aniline; sulfonamide antibiotic; thiadiazoles
propamidine	[no description available]	low	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
hexamidine	[no description available]	low	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
o-4-methylthymine	[no description available]	low	0	aromatic ether; methylthymine	human metabolite
fenclofenac	[no description available]	low	0	aromatic ether
tetraiodothyroacetic acid	[no description available]	low	0	2-halophenol; aromatic ether; iodophenol; monocarboxylic acid	apoptosis inducer; human metabolite; thyroid hormone
fluazuron	[no description available]	low	0	aromatic ether; chloropyridine; monochlorobenzenes; N-acylurea; organochlorine acaricide; organofluorine acaricide; phenylureas	acaricide; mite growth regulator
etiroxate	[no description available]	low	0	aromatic ether
etofamide	[no description available]	low	0	aromatic ether
d 888	[no description available]	low	0	aromatic ether; nitrile; tertiary amino compound	anti-arrhythmia drug; calcium channel blocker; vasodilator agent
esreboxetine	[no description available]	low	0	aromatic ether
guaethol	[no description available]	low	0	aromatic ether; phenols; volatile organic compound	flavouring agent
spiramide	[no description available]	low	0	aromatic ether; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; serotonergic antagonist
5'-nitro-2'-propoxyacetanilide	[no description available]	low	0	aromatic ether; C-nitro compound
suberosin	[no description available]	low	0	aromatic ether; coumarins	anticoagulant; plant metabolite
4-methoxyestradiol	[no description available]	low	0	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; phenols	estrogen; human metabolite; rat metabolite
toltrazuril	[no description available]	low	0	aromatic ether
plafibride	[no description available]	low	0	aromatic ether
cinitapride	[no description available]	low	0	aromatic ether; C-nitro compound
isoscopoletin	[no description available]	low	0	aromatic ether; hydroxycoumarin	plant metabolite
ethofenprox	[no description available]	low	0	aromatic ether	pyrethroid ether insecticide
uk 68798	[no description available]	low	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
fenoxypropazine	[no description available]	low	0	aromatic ether
fluphenacur	[no description available]	low	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; N-acylurea; organofluorine compound
amezinium	[no description available]	low	0	aromatic ether; primary arylamine; pyridazinium ion	adrenergic uptake inhibitor; antihypotensive agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; sympathomimetic agent
rubrofusarin	[no description available]	low	0	aromatic ether; benzochromenone; phenols; polyketide	biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; fungal metabolite
triasulfuron	[no description available]	low	0	1,3,5-triazines; aromatic ether; N-sulfonylurea; organochlorine compound	agrochemical; herbicide
dauricine	[no description available]	low	0	aromatic ether; bisbenzylisoquinoline alkaloid; isoquinolines; phenols; tertiary amino compound	plant metabolite
uvaretin	[no description available]	low	0	aromatic ether; dihydrochalcones; polyketide; resorcinol	antineoplastic agent; plant metabolite
fangchinoline	[no description available]	low	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
prochloraz	[no description available]	low	0	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
stictic acid	[no description available]	low	0	aromatic ether
pramoxine hydrochloride	[no description available]	low	0	aromatic ether
4-methoxybenzylamine	[no description available]	low	0	aralkylamino compound; aromatic ether; primary amino compound
xanthurenic acid 8-methyl ether	[no description available]	low	0	aromatic ether; monohydroxyquinoline; quinolinemonocarboxylic acid	carcinogenic agent; metabolite; mouse metabolite
adriamycinol	[no description available]	low	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
difenoconazole	[no description available]	low	0	aromatic ether; conazole fungicide; cyclic ketal; dioxolane; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
a 8947	[no description available]	low	0	aromatic ether; biaryl; N-sulfonylurea; pyrazole pesticide; tetrazoles	EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
thifluzamide	[no description available]	low	0	1,3-thiazoles; anilide fungicide; aromatic amide; aromatic ether; dibromobenzene; organofluorine compound	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
ethylhydrocupreine	[no description available]	low	0	aromatic ether; cinchona alkaloid	EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
7,8-dihydromethysticin	[no description available]	low	0	2-pyranones; aromatic ether
4,5-dimethoxy-2-nitrobenzaldehyde	[no description available]	low	0	aromatic ether; C-nitro compound
bisphenol f diglycidyl ether	[no description available]	low	0	aromatic ether; diarylmethane; epoxide
oryzemate	[no description available]	low	0	1,2-benzisothiazole; aromatic ether; benzothiazole fungicide; sulfone	antifungal agrochemical; plant activator
bitertanol	[no description available]	low	0	aromatic ether; biphenyls; secondary alcohol; triazoles
fluazifop	[no description available]	low	0	aromatic ether; monocarboxylic acid; organofluorine compound; pyridines
diflufenican	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; pyridinecarboxamide	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
hexafluoron	[no description available]	low	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; N-acylurea; organochlorine insecticide; organofluorine insecticide
diethofencarb	[no description available]	low	0	aromatic ether; carbamate ester; carbanilate fungicide	antifungal agrochemical
pyriproxyfen	[no description available]	low	0	aromatic ether; pyridines	juvenile hormone mimic
methyl 2-(((((4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl)amino)carbonyl)amino)sulfonyl)benzoate	[no description available]	low	0	aromatic ether; benzoate ester; diamino-1,3,5-triazine; methyl ester; N-sulfonylurea	EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
dpx e9636	[no description available]	low	0	aromatic ether; N-sulfonylurea; pyridines; pyrimidines; sulfone	environmental contaminant; herbicide; xenobiotic
aclonifen	[no description available]	low	0	aromatic ether; C-nitro compound; monochlorobenzenes; primary amino compound; substituted aniline	agrochemical; carotenoid biosynthesis inhibitor; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
cinosulfuron	[no description available]	low	0	aromatic ether
clodinafop-propargyl	[no description available]	low	0	aromatic ether; carboxylic ester; organochlorine compound; organofluorine compound; propyzamide; pyridines	agrochemical; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; herbicide
triflusulfuron-methyl	[no description available]	low	0	1,3,5-triazines; aromatic ether; benzoate ester; methyl ester; N-sulfonylurea; organofluorine compound; tertiary amino compound	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; proherbicide
vestitol	[no description available]	low	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	anti-inflammatory agent; phytoalexin; plant metabolite
laudanine	[no description available]	low	0	aromatic ether; benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; phenols; racemate
cryptopleurine	[no description available]	low	0	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	antineoplastic agent; antiviral agent; protein synthesis inhibitor
6-hydroxymethylmexiletine	[no description available]	low	0	aromatic ether
4-hydroxymexiletine	[no description available]	low	0	aromatic ether; phenols
cloquintocet-mexyl	[no description available]	low	0	aromatic ether; carboxylic ester; organochlorine compound; quinolines
novaluron	[no description available]	low	0	aromatic ether; benzoylurea insecticide; monochlorobenzenes; organofluorine compound
bursehernin	[no description available]	low	0	aromatic ether; benzodioxoles; butan-4-olide; lignan	plant metabolite
2,2',4,4'-tetrabromodiphenyl ether	[no description available]	low	0	aromatic ether; organobromine compound
allocryptopine	[no description available]	low	0	aromatic ether; cyclic acetal; cyclic ketone; dibenzazecine alkaloid; organic heterotetracyclic compound; tertiary amino compound
sporidesmin	[no description available]	low	0	aromatic ether; cyclic ketone; diketone; organic disulfide; organic heteropentacyclic compound; organochlorine compound; secondary alcohol; tertiary alcohol; tertiary amino compound	mycotoxin; Wnt signalling activator
syringaresinol	[no description available]	low	0	aromatic ether; furofuran; lignan; polyether; polyphenol	plant metabolite
p-methoxy-n-methylphenethylamine	[no description available]	low	0	aromatic ether; secondary amino compound	metabolite
aflatoxin q1	[no description available]	low	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human xenobiotic metabolite
u 73122	[no description available]	low	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
cyfluthrin	[no description available]	low	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound; organofluorine compound	agrochemical; pyrethroid ester insecticide
norverapamil	[no description available]	low	0	aromatic ether; nitrile; polyether; secondary amino compound
fumitremorgin a	[no description available]	low	0	aromatic ether; diol; indole alkaloid; organic heterohexacyclic compound; organic peroxide	mycotoxin
deguelin	[no description available]	low	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
aristolochic acid ii	[no description available]	low	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
tephrosin	[no description available]	low	0	aromatic ether; cyclic ketone; organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; pesticide
alpha-hydroxymetoprolol	[no description available]	low	0	aromatic ether
5-(tetradecyloxy)-2-furancarboxylic acid	[no description available]	low	0	aromatic ether; furoic acid	antineoplastic agent; apoptosis inducer; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; PPARalpha agonist
tafenoquine	[no description available]	low	0	(trifluoromethyl)benzenes; aminoquinoline; aromatic ether; primary amino compound; secondary amino compound
5-hydroxymethylomeprazole	[no description available]	low	0	aromatic ether; benzimidazoles; pyridines; sulfoxide	drug metabolite
mosapride	[no description available]	low	0	aromatic ether; benzamides; monochlorobenzenes; monofluorobenzenes; morpholines; secondary carboxamide; substituted aniline; tertiary amino compound
ym 12617	[no description available]	low	0	aromatic ether; secondary amino compound; sulfonamide
gefitinib	[no description available]	low	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
cgp 28392	[no description available]	low	0	aromatic ether
sodium-binding benzofuran isophthalate	[no description available]	low	0	1-benzofurans; aromatic ether; crown compound; tetracarboxylic acid	fluorochrome
garenoxacin	[no description available]	low	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
ay 25545	[no description available]	low	0	acetate ester; aromatic ether; C-glycosyl compound; naphthoisochromene; olefinic compound; phenols; tertiary amine	antimicrobial agent; antineoplastic agent; bacterial metabolite
b 823-08	[no description available]	low	0	aromatic ether
cyclazosin	[no description available]	low	0	aromatic amide; aromatic ether; furans; monocarboxylic acid amide; quinazolines; quinoxaline derivative	adenosine A2A receptor antagonist
ivabradine	[no description available]	low	0	aromatic ether; benzazepine; carbobicyclic compound; tertiary amino compound	cardiotonic drug
febuxostat	[no description available]	low	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
marsupsin	[no description available]	low	0	1-benzofurans; aromatic ether; polyphenol	antilipemic drug; hypoglycemic agent; metabolite
6,6'-bieckol	[no description available]	low	0	aromatic ether; oxacycle; phlorotannin	anti-HIV-1 agent; metabolite; radical scavenger
xibenolol	[no description available]	low	0	aromatic ether
cicloprolol	[no description available]	low	0	aromatic ether
chs 828	[no description available]	low	0	aromatic ether
2-(4-methoxyphenoxy)propanoic acid	[no description available]	low	0	aromatic ether; carboxylic acid
moxifloxacin	[no description available]	low	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
rp 73401	[no description available]	low	0	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
2,2',4,4',5,5'-hexabrominated diphenyl ether	[no description available]	low	0	aromatic ether; organobromine compound
varespladib	[no description available]	low	0	aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor
birb 796	[no description available]	low	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
schizandrin b	[no description available]	low	0	aromatic ether; cyclic acetal; organic heterotetracyclic compound; oxacycle; tannin	anti-asthmatic agent; anti-inflammatory agent; antilipemic drug; antioxidant; apoptosis inhibitor; hepatoprotective agent; nephroprotective agent; neuroprotective agent; plant metabolite
s 23121	[no description available]	low	0	aromatic ether; dicarboximide; monochlorobenzenes; monofluorobenzenes; pyrroline; terminal acetylenic compound
acrovestone	[no description available]	low	0	acetophenones; aromatic ether; olefinic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; plant metabolite
corytuberine	[no description available]	low	0	aporphine alkaloid; aromatic ether; organic heterotetracyclic compound; polyphenol; tertiary amino compound	plant metabolite
actinodaphine	[no description available]	low	0	aporphine alkaloid; aromatic ether; organic heteropentacyclic compound; phenols; secondary amino compound	antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; plant metabolite; platelet aggregation inhibitor; topoisomerase inhibitor
isohomovanillic acid	[no description available]	low	0	aromatic ether; phenols; phenylacetic acids	metabolite
3,5-diiodothyropropionic acid	[no description available]	low	0	aromatic ether; monocarboxylic acid; organoiodine compound; phenols
7,8-dihydro-5,6-dehydrokawain	[no description available]	low	0	2-pyranones; aromatic ether
4-amino-2-methoxypyrimidine	[no description available]	low	0	aminopyrimidine; aromatic ether; methylcytosine	metabolite
aristolochic acid D	[no description available]	low	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; nephrotoxin; toxin
myricanone	[no description available]	low	0	aromatic ether; cyclic ketone; diarylheptanoid; methoxybenzenes; phenols	antineoplastic agent; plant metabolite
pannarin	[no description available]	low	0	aldehyde; aromatic ether; depsidones; organic heterotricyclic compound; organochlorine compound; phenols	antimicrobial agent; antineoplastic agent; apoptosis inducer; lichen metabolite
aminopotentidine	[no description available]	low	0	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist
aristolochic acid c	[no description available]	low	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
pluviatolide	[no description available]	low	0	aromatic ether; benzodioxoles; butan-4-olide; lignan; phenols	plant metabolite
erysodine	[no description available]	low	0	aromatic ether; diether; Erythrina alkaloid; organic heterotetracyclic compound; phenols	antiparasitic agent; nicotinic antagonist; phytogenic insecticide
erlotinib	[no description available]	low	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
rubrofusarin B	[no description available]	low	0	aromatic ether; benzochromenone; naphtho-gamma-pyrone; phenols; polyketide	Aspergillus metabolite
ly 293111	[no description available]	low	0	aromatic ether
enrasentan	[no description available]	low	0	aromatic ether; benzodioxoles; indanes; monocarboxylic acid; monomethoxybenzene; primary alcohol	antihypertensive agent; endothelin receptor antagonist
quizalofop	[no description available]	low	0	aromatic ether; monocarboxylic acid; organochlorine compound; quinoxaline derivative
cyhalofop-butyl	[no description available]	low	0	aromatic ether
cyperin	[no description available]	low	0	aromatic ether
aflatoxin b1	[no description available]	low	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
etravirine	[no description available]	low	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
5-o-methyllicoricidin	[no description available]	low	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	antibacterial agent; plant metabolite
pronuciferine	[no description available]	low	0	aromatic ether; cyclic ketone; isoquinoline alkaloid; isoquinolines; organic heterotetracyclic compound	plant metabolite
dronedarone	[no description available]	low	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
famoxadone	[no description available]	low	0	aromatic ether; carbohydrazide; oxazolidinone
cimicoxib	[no description available]	low	0	aromatic ether; imidazoles; organochlorine compound; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
sorafenib	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
dabuzalgron	[no description available]	low	0	aromatic ether; imidazoles; monochlorobenzenes; sulfonamide	alpha-adrenergic agonist
fonsecin	[no description available]	low	0	aromatic ether; cyclic hemiketal; heptaketide; naphtho-gamma-pyrone; phenols	Aspergillus metabolite; marine metabolite
lasofoxifene	[no description available]	low	0	aromatic ether; N-alkylpyrrolidine; naphthols; tetralins	antineoplastic agent; bone density conservation agent; cardioprotective agent; estrogen receptor agonist; estrogen receptor antagonist
(+-)-Dihydromethysticin	[no description available]	low	0	2-pyranones; aromatic ether
2-[2-[2-(2-aminophenoxy)ethoxy]ethoxy]aniline	[no description available]	low	0	aromatic ether; substituted aniline
chondocurine (1beta)-(+-)-isomer	[no description available]	low	0	aromatic ether
1-methyl-4-prop-2-enoxy-2-pyrimidinone	[no description available]	low	0	aromatic ether; pyrimidone
noscapine	[no description available]	low	0	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
4-[4-(3-methyl-4-nitrophenoxy)butoxy]benzonitrile	[no description available]	low	0	aromatic ether; C-nitro compound
lariciresinol	[no description available]	low	0	aromatic ether; lignan; oxolanes; phenols; primary alcohol	antifungal agent; plant metabolite
tryptoquivaline	[no description available]	low	0	aromatic ether; indole alkaloid; organic heteropentacyclic compound	breast cancer resistance protein inhibitor; mycotoxin
2-methoxyestrone	[no description available]	low	0	17-oxo steroid; 3-hydroxy steroid; alicyclic ketone; aromatic ether; phenolic steroid; phenols	human metabolite; mouse metabolite
win 54954	[no description available]	low	0	aromatic ether
silychristin	[no description available]	low	0	1-benzofurans; aromatic ether; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	lipoxygenase inhibitor; metabolite; prostaglandin antagonist; radical scavenger
cleomiscosin a	[no description available]	low	0	aromatic ether; delta-lactone; organic heterotricyclic compound; phenols; primary alcohol	anti-inflammatory agent; metabolite
bispyribac	[no description available]	low	0	aromatic ether; benzoic acids; monocarboxylic acid; pyrimidines	herbicide
petunidin-3-glucoside	[no description available]	low	0	anthocyanin cation; aromatic ether; beta-D-glucoside	antioxidant; metabolite
malvidin-3-glucoside	[no description available]	low	0	anthocyanin cation; aromatic ether; beta-D-glucoside	metabolite
dioncophylline c	[no description available]	low	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthols	antimalarial; antiplasmodial drug; metabolite
stigmatellin	[no description available]	low	0	aromatic ether; chromones; olefinic compound; phenols	bacterial metabolite; quinol oxidation site inhibitor
roflumilast	[no description available]	low	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
teniposide	[no description available]	low	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
prinomastat	[no description available]	low	0	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor
posaconazole	[no description available]	low	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
gancaonin I	[no description available]	low	0	1-benzofurans; aromatic ether; resorcinols	antibacterial agent; plant metabolite
glycyrin	[no description available]	low	0	aromatic ether; coumarins; hydroxyisoflavans	antibacterial agent; metabolite; plant metabolite
glyasperin D	[no description available]	low	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	plant metabolite
licoricidin	[no description available]	low	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	antibacterial agent; plant metabolite
egonol	[no description available]	low	0	1-benzofurans; aromatic ether; benzodioxoles; primary alcohol	plant metabolite
N-ethylharmine	[no description available]	low	0	aromatic ether; beta-carbolines; semisynthetic derivative	anti-HIV agent
pf 1163a	[no description available]	low	0	aromatic ether; lactam; macrolide antibiotic; secondary alcohol	antifungal agent; Penicillium metabolite
pf 1163b	[no description available]	low	0	aromatic ether; lactam; macrolide antibiotic	antifungal agent; Penicillium metabolite
licocoumarone	[no description available]	low	0	1-benzofurans; aromatic ether; resorcinols	antibacterial agent; apoptosis inducer; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide	[no description available]	low	0	aromatic ether
LSM-22807	[no description available]	low	0	aromatic ether
N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide	[no description available]	low	0	aromatic ether
piperlactam s	[no description available]	low	0	alkaloid; aromatic ether; gamma-lactam; organic heterotetracyclic compound; phenols	anti-inflammatory agent; antioxidant; plant metabolite
5,5-dioxo-1-(4-phenoxyphenyl)-3a,4,6,6a-tetrahydro-3H-thieno[3,4-b]pyrrol-2-one	[no description available]	low	0	aromatic ether
antofine	[no description available]	low	0	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	angiogenesis inhibitor; anti-inflammatory agent; antimicrobial agent; antineoplastic agent; antiviral agent; phytotoxin; plant metabolite
xanthohumol	[no description available]	low	0	aromatic ether; chalcones; polyphenol	anti-HIV-1 agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor; metabolite
2-phenoxy-N-(2-pyridinyl)butanamide	[no description available]	low	0	aromatic ether
6-amino-4-(2-ethoxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	aromatic ether; pyranopyrazole
N-[4-[4-[[1-oxo-2-(1-pyrrolidinyl)ethyl]amino]phenoxy]phenyl]-2-(1-pyrrolidinyl)acetamide	[no description available]	low	0	aromatic ether
2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole	[no description available]	low	0	aromatic ether
2-[[5-(phenoxymethyl)-4-(2-phenylethyl)-1,2,4-triazol-3-yl]thio]acetamide	[no description available]	low	0	aromatic ether
1-(8-methyl-2,5,11,14-tetraoxa-8-azabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)ethanol	[no description available]	low	0	aromatic ether
3-[2-(3-phenoxypropyl)-5-tetrazolyl]pyridine	[no description available]	low	0	aromatic ether
1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole	[no description available]	low	0	aromatic ether
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-[[5-[(3-methylphenoxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide	[no description available]	low	0	aromatic ether
6-amino-4-[3-ethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	aromatic ether; pyranopyrazole
2-[[5-[(2,3-dimethylphenoxy)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-1-thiophen-2-ylethanone	[no description available]	low	0	aromatic ether
(1-methyl-2-imidazolyl)-(4-phenylmethoxyphenyl)methanol	[no description available]	low	0	aromatic ether
5-(3-butoxyphenyl)-1,3,4-thiadiazol-2-amine	[no description available]	low	0	aromatic ether
3-(2-ethoxy-6-methyl-3-pyridinyl)-5-(2-pyridinyl)-1,2,4-oxadiazole	[no description available]	low	0	aromatic ether
6-(3,4,5-triethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	[no description available]	low	0	aromatic ether; triazolothiadiazole
4-(1-benzotriazolyl)-5-(2-methoxyphenoxy)benzene-1,2-dicarbonitrile	[no description available]	low	0	aromatic ether
4-cyclohexyl-3-[(3-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione	[no description available]	low	0	aromatic ether
7-ethoxy-9-nitro-5H-benzo[b][1,4]benzoxazepin-6-one	[no description available]	low	0	aromatic ether
4-[4-(2-quinoxalinyl)phenoxy]benzene-1,2-dicarbonitrile	[no description available]	low	0	aromatic ether
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(phenoxymethyl)-4-triazolecarboxylic acid ethyl ester	[no description available]	low	0	aromatic ether
2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide	[no description available]	low	0	aromatic ether
2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide	[no description available]	low	0	aromatic ether
5-[(4-ethylphenoxy)methyl]-N-(2-pyridinylmethyl)-2-furancarboxamide	[no description available]	low	0	aromatic ether
7-methoxy-3,5-dimethyl-2-thiazolo[4,5-d]pyrimidinethione	[no description available]	low	0	aromatic ether
N-[4-(4-ethylphenyl)-2-thiazolyl]carbamic acid phenyl ester	[no description available]	low	0	aromatic ether
2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	aromatic ether
1-[[3-(4-chlorophenoxy)phenyl]methyl]-4-ethylpiperazine	[no description available]	low	0	aromatic ether
2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol	[no description available]	low	0	aromatic ether; C-nitro compound
4-[[4-(ethylamino)-6-(methylthio)-1,3,5-triazin-2-yl]oxy]benzoic acid ethyl ester	[no description available]	low	0	aromatic ether
5-ethyl-3-[[4-(2-methylpropoxy)phenyl]methylthio]-1H-1,2,4-triazole	[no description available]	low	0	aromatic ether
[4-[(2-fluorophenyl)methoxy]phenyl]-(1-pyrrolidinyl)methanethione	[no description available]	low	0	aromatic ether
5-[(2-chlorophenoxy)methyl]-3-pyridin-4-yl-1,2,4-oxadiazole	[no description available]	low	0	aromatic ether
4-(4-phenylmethoxyphenyl)thiadiazole	[no description available]	low	0	aromatic ether
N-methyl-2-[[4-methyl-5-[(4-nitrophenoxy)methyl]-1,2,4-triazol-3-yl]thio]acetamide	[no description available]	low	0	aromatic ether; C-nitro compound
2-[[5-(4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-1-(4-morpholinyl)ethanone	[no description available]	low	0	aromatic ether
4-(3-pyridinyloxy)benzene-1,2-dicarbonitrile	[no description available]	low	0	aromatic ether
N-tert-butyl-2-(4-chloro-3-methylphenoxy)acetamide	[no description available]	low	0	aromatic ether
1-(2-furanylmethyl)-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
1-(2-methylpropyl)-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
1-cyclopentyl-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
5-[(4-ethoxyphenoxy)methyl]-N-(3-pyridinyl)-2-furancarboxamide	[no description available]	low	0	aromatic ether
2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide	[no description available]	low	0	aromatic ether
5-[(2-chlorophenoxy)methyl]-N-(2-thiazolyl)-2-furancarboxamide	[no description available]	low	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide	[no description available]	low	0	aromatic ether
N-(4,5-dihydrothiazol-2-yl)-2-(2-methylphenoxy)acetamide	[no description available]	low	0	aromatic ether
5-(2-fluorophenoxy)-1-methyl-3-nitro-1,2,4-triazole	[no description available]	low	0	aromatic ether
1-methyl-5-(1-naphthalenyloxy)-4-nitroimidazole	[no description available]	low	0	aromatic ether
curcumin	[no description available]	low	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea	[no description available]	low	0	aromatic ether; C-nitro compound
1-cyclopentyl-3-(2-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
N-(1-ethyl-2-benzimidazolyl)-5-[(4-methyl-2-nitrophenoxy)methyl]-2-furancarboxamide	[no description available]	low	0	aromatic ether; C-nitro compound
2-chloro-12-(4-methoxyphenyl)sulfonylquinoxalino[2,3-b][1,4]benzoxazine	[no description available]	low	0	aromatic ether
1-(3-methoxy-5-nitrophenyl)-3-(4-methylphenyl)urea	[no description available]	low	0	aromatic ether; C-nitro compound
2-(2-bromo-4-chlorophenoxy)-N-cyclohexyl-N-methylacetamide	[no description available]	low	0	aromatic ether
2-furanyl-[4-(4-phenoxyphenyl)sulfonyl-1-piperazinyl]methanone	[no description available]	low	0	aromatic ether
4-(2-methoxyphenoxy)-N-(3-pyridinyl)benzenesulfonamide	[no description available]	low	0	aromatic ether
1-(3-chlorophenyl)-3-(2-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
N-[3-[2-(1-azepanyl)-4,5-dicyanophenoxy]phenyl]acetamide	[no description available]	low	0	aromatic ether
2,5-dimethoxy-N-(4-phenoxyphenyl)benzenesulfonamide	[no description available]	low	0	aromatic ether
4-[[4-(dimethylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]benzoic acid methyl ester	[no description available]	low	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	[no description available]	low	0	aromatic ether
1-[4-[[4-(2-chloro-6-nitrophenoxy)phenyl]methoxy]phenyl]ethanone	[no description available]	low	0	aromatic ether
N-[4-[[2-(4-hydroxyphenyl)-1,3-dioxo-5-isoindolyl]oxy]phenyl]-2,2-dimethylpropanamide	[no description available]	low	0	aromatic ether
N-[[4-(4-chlorophenoxy)anilino]-sulfanylidenemethyl]benzamide	[no description available]	low	0	aromatic ether
2-(4-fluorophenoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide	[no description available]	low	0	aromatic ether
4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-propan-2-ylbenzenesulfonamide	[no description available]	low	0	aromatic ether
4-(4-tert-butylphenoxy)-5-methoxy-2-phenylpyrimidine	[no description available]	low	0	aromatic ether
4-phenoxy-2-phenyl-5-pyrimidinecarboxylic acid ethyl ester	[no description available]	low	0	aromatic ether
Src Inhibitor-1	[no description available]	low	0	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
N-[2,5-dioxo-6-(4-phenoxyphenyl)-3-pyrano[3,2-c]pyridinyl]benzamide	[no description available]	low	0	aromatic ether
2-(4-chlorophenoxy)-4-(dimethylamino)-3-pyridinecarbonitrile	[no description available]	low	0	aromatic ether
6-methyl-5-[2-(2-methylphenoxy)ethyl]-2-sulfanylidene-1H-pyrimidin-4-one	[no description available]	low	0	aromatic ether
4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone	[no description available]	low	0	aromatic ether
N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine	[no description available]	low	0	aromatic ether
4-(phenylmethyl)-3-[2-(4-propoxyphenyl)ethyl]-1H-1,2,4-triazole-5-thione	[no description available]	low	0	aromatic ether
1-[[1-oxo-3-(4-propan-2-yloxyphenyl)propyl]amino]-3-(phenylmethyl)thiourea	[no description available]	low	0	aromatic ether
N-[3-(3-methylphenoxy)-5-nitrophenyl]-2-(3-nitro-1,2,4-triazol-1-yl)acetamide	[no description available]	low	0	aromatic ether
N-bis(2-fluorophenoxy)phosphoryl-3,4-dimethylaniline	[no description available]	low	0	aromatic ether
2-[[4-(2-ethoxyanilino)-6-(4-ethoxyanilino)-2-pyrimidinyl]methylidene]propanedinitrile	[no description available]	low	0	aromatic ether
5-methyl-3-[(4-pentoxyphenyl)methylthio]-1H-1,2,4-triazole	[no description available]	low	0	aromatic ether
4,5-dichloro-1-[2-(4-chlorophenoxy)ethyl]imidazole	[no description available]	low	0	aromatic ether
1-butyl-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	aromatic ether
N-(3-cyano-2-thiophenyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]acetamide	[no description available]	low	0	aromatic ether
2-(2-bromophenyl)-5-[(2-chlorophenoxy)methyl]-1,3,4-oxadiazole	[no description available]	low	0	aromatic ether
5-(4-ethoxyphenyl)-N-(3,4,5,6-tetrahydro-2H-azepin-7-yl)-1,3,4-oxadiazol-2-amine	[no description available]	low	0	aromatic ether
4-(4-chloro-2-methylphenoxy)-1-(4-morpholinyl)-1-butanone	[no description available]	low	0	aromatic ether
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine	[no description available]	low	0	aromatic ether
2-[2-(4-chlorophenoxy)ethylthio]pyrimidine	[no description available]	low	0	aromatic ether
5-(3-phenoxypropyl)-3-(3-pyridinyl)-1,2,4-oxadiazole	[no description available]	low	0	aromatic ether
N-[(3-ethoxy-2-prop-2-enoxyphenyl)methyl]-2-thiazolamine	[no description available]	low	0	aromatic ether
2-(2-bromophenoxy)-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	aromatic ether
4-[2-[(4-chlorophenyl)thio]ethoxy]-3-ethoxybenzaldehyde	[no description available]	low	0	aromatic ether
1-(3-fluorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrophenyl)-4H-pyridine-3,5-dicarboxylic acid diethyl ester	[no description available]	low	0	aromatic ether; C-nitro compound
5-(2-ethoxyphenyl)-3H-1,3,4-oxadiazole-2-thione	[no description available]	low	0	aromatic ether
N-tert-butyl-4-(2-fluorophenoxy)-1-butanamine	[no description available]	low	0	aromatic ether
N-butyl-4-phenoxy-1-butanamine	[no description available]	low	0	aromatic ether
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-methylphenyl) ester	[no description available]	low	0	aromatic ether
1,3-dimethyl-5-[[2-[2-(4-nitrophenoxy)ethoxy]phenyl]methylidene]-1,3-diazinane-2,4,6-trione	[no description available]	low	0	aromatic ether; C-nitro compound
4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine	[no description available]	low	0	aromatic ether
2-[2-(3-ethylphenoxy)ethyl]propanedioic acid diethyl ester	[no description available]	low	0	aromatic ether
2,3-dihydro-1,4-dioxin-5-carboxylic acid [2-[4-[4-(2-methylbutan-2-yl)phenoxy]anilino]-2-oxoethyl] ester	[no description available]	low	0	aromatic ether
1-[3-(2-bromo-4-chlorophenoxy)propyl]-4-methylpiperidine	[no description available]	low	0	aromatic ether
N4-(2-methoxyphenyl)benzene-1,4-diamine	[no description available]	low	0	aromatic ether; substituted aniline
4-(1H-benzimidazol-2-ylthio)butanoic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester	[no description available]	low	0	aromatic ether
2-phenoxybenzoic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester	[no description available]	low	0	aromatic ether
1-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]ethanone	[no description available]	low	0	aromatic ether
N-[6-amino-1-(2-methylpropyl)-2,4-dioxo-5-pyrimidinyl]-2-(2-methylphenoxy)-N-(2-methylpropyl)acetamide	[no description available]	low	0	aromatic ether
4-[[6-[(2-methyl-5-thieno[2,3-e][1,3]benzothiazolyl)oxy]-3-pyridinyl]sulfonyl]morpholine	[no description available]	low	0	aromatic ether
5-(3-fluorophenoxy)-8-nitroisoquinoline	[no description available]	low	0	aromatic ether
1-[4-(2-prop-2-enylphenoxy)butyl]pyrrolidine	[no description available]	low	0	aromatic ether
2-(2,4-dibromophenoxy)-N-[oxo-(propan-2-ylamino)methyl]acetamide	[no description available]	low	0	aromatic ether
4-phenoxyphenyl 4-hydroxypiperidine-1-carboxylate	[no description available]	low	0	aromatic ether
N'-benzoyl-5-(3,5-dichlorophenoxy)-2-furancarbohydrazide	[no description available]	low	0	aromatic ether
1-[2-[(4-chlorophenoxy)methyl]-4-thiazolyl]ethanone	[no description available]	low	0	aromatic ether
5-(benzyloxy)-2-(hydroxymethyl)-1,4-dihydropyridin-4-one	[no description available]	low	0	aromatic ether
2-(4-aminophenoxy)isophthalonitrile	[no description available]	low	0	aromatic ether
N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine	[no description available]	low	0	aromatic ether
N-[(2-chloro-6-phenoxyphenyl)methyl]benzenesulfonamide	[no description available]	low	0	aromatic ether
N-[5-(tert-butyl)-3-isoxazolyl]-N'-[2-(trifluoromethoxy)phenyl]urea	[no description available]	low	0	aromatic ether
6-(4-methoxyphenoxy)-2-imidazo[1,2-b]pyridazinecarboxylic acid ethyl ester	[no description available]	low	0	aromatic ether
2-fluoro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]acetamide	[no description available]	low	0	aromatic ether; C-nitro compound
2-amino-4-(4,5-dimethoxy-2-nitrophenyl)-7,7-dimethyl-5-oxo-6,8-dihydro-4H-1-benzopyran-3-carbonitrile	[no description available]	low	0	aromatic ether; C-nitro compound
2,4-dichloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide	[no description available]	low	0	aromatic ether; C-nitro compound
1-anilino-3-[4-(3-anilino-2-hydroxypropoxy)phenoxy]-2-propanol	[no description available]	low	0	aromatic ether
1-[4-(3-ethoxyphenoxy)butyl]imidazole	[no description available]	low	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide	[no description available]	low	0	aromatic ether
1-[[2-(2,4-difluorophenoxy)-1-oxopropyl]amino]-3-(2-oxolanylmethyl)thiourea	[no description available]	low	0	aromatic ether
N-[[(5-bromo-6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-2-(2-chlorophenoxy)acetamide	[no description available]	low	0	aromatic ether
2-[(4-chlorophenyl)sulfonyl-methylamino]-N-(4-methoxy-2-nitrophenyl)acetamide	[no description available]	low	0	aromatic ether; C-nitro compound
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide	[no description available]	low	0	aromatic ether
1-(2-fluorophenyl)-3-(4-methoxy-2-nitrophenyl)urea	[no description available]	low	0	aromatic ether; C-nitro compound
2-[[5-[(2-fluorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide	[no description available]	low	0	aromatic ether
cyclopropanecarboxylic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester	[no description available]	low	0	aromatic ether
toremifene	[no description available]	low	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
dieckol	[no description available]	low	0	aromatic ether; oxacycle; phlorotannin	anticoagulant; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; metabolite; radical scavenger
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine	[no description available]	low	0	aromatic ether
naproxol	[no description available]	low	0	aromatic ether	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
tamoxifen n-oxide	[no description available]	low	0	aromatic ether; tertiary amine oxide	anti-estrogen; metabolite
diafenthiuron	[no description available]	low	0	aromatic ether; thiourea acaricide; thiourea insecticide	oxidative phosphorylation inhibitor; proinsecticide
ospemifene	[no description available]	low	0	aromatic ether; organochlorine compound; primary alcohol	anti-inflammatory agent; antineoplastic agent; estrogen receptor modulator
tandutinib	[no description available]	low	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
zd 6474	[no description available]	low	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
adefovir	[no description available]	low	0	aromatic ether; aromatic ketone; biaryl; cyclic ketone; naphtho-gamma-pyrone; organooxygen heterocyclic antibiotic; polyphenol	antimalarial; Aspergillus metabolite; marine metabolite
3-chloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide	[no description available]	low	0	aromatic ether; C-nitro compound
N-(2-hydroxyethyl)-4-[2-nitro-4-(trifluoromethyl)phenoxy]benzamide	[no description available]	low	0	aromatic ether
N'-[2-[(4-amino-5-cyano-2-pyrimidinyl)thio]-1-oxoethyl]-2-(4-methylphenoxy)acetohydrazide	[no description available]	low	0	aromatic ether
N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide	[no description available]	low	0	aromatic ether
6-amino-4-(2-ethoxy-4-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	aromatic ether; pyranopyrazole
1-[(2-ethoxyphenyl)methyl]-3-thiophen-2-ylurea	[no description available]	low	0	aromatic ether
quinoxyfen	[no description available]	low	0	aromatic ether; monofluorobenzenes; organochlorine compound; quinolines	antifungal agrochemical
nafadotride	[no description available]	low	0	aromatic ether; naphthalenecarboxamide; nitrile; pyrrolidines; tertiary amino compound	dopaminergic antagonist
1-(1-naphthalenyl)-3-[[2-(2-nitrophenoxy)-1-oxoethyl]amino]urea	[no description available]	low	0	aromatic ether; C-nitro compound
2-methyl-1,3-bis(phenylmethoxy)benzene	[no description available]	low	0	aromatic ether
1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)urea	[no description available]	low	0	aromatic ether
3-[(4-ethylphenoxy)methyl]-4-(6-methylheptan-2-yl)-1H-1,2,4-triazole-5-thione	[no description available]	low	0	aromatic ether
2-chloro-N-(2-methyl-6-oxo-5H-benzo[b][1,4]benzoxazepin-8-yl)acetamide	[no description available]	low	0	aromatic ether
5-(benzenesulfonyl)-4-(2,6-dimethylphenoxy)-2-phenylpyrimidine	[no description available]	low	0	aromatic ether
4-(2-methylphenoxy)-6-phenylfuro[2,3-d]pyrimidine	[no description available]	low	0	aromatic ether
1-[4-(2-chlorophenoxy)butyl]imidazole	[no description available]	low	0	aromatic ether; imidazoles; monochlorobenzenes
N-(2-chlorophenyl)-4-[[(2-methoxy-4-nitroanilino)-sulfanylidenemethyl]hydrazo]-4-oxobutanamide	[no description available]	low	0	aromatic ether; C-nitro compound
N-(2-methoxy-4-nitrophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide	[no description available]	low	0	aromatic ether; C-nitro compound
N-[4-(phenoxymethyl)-2-thiazolyl]-1-adamantanecarboxamide	[no description available]	low	0	aromatic ether
hydroxypioglitazone	[no description available]	low	0	aromatic ether; pyridines; thiazolidinediones	human xenobiotic metabolite
sc 560	[no description available]	low	0	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
sc-19220	[no description available]	low	0	aromatic ether
5-methyl-4-(3-phenoxyphenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-6-carboxylic acid ethyl ester	[no description available]	low	0	aromatic ether
8-[4-(4-fluorophenoxy)-3-nitrophenyl]-7-(2-hydroxyethyl)-3-(phenylmethyl)purine-2,6-dione	[no description available]	low	0	aromatic ether
2-phenoxybenzoic acid [2-oxo-2-(propan-2-ylamino)ethyl] ester	[no description available]	low	0	aromatic ether
2-(4-bromophenoxy)-N'-[2-[(4-methyl-1,2,4-triazol-3-yl)thio]-1-oxoethyl]acetohydrazide	[no description available]	low	0	aromatic ether
2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile	[no description available]	low	0	aromatic ether; substituted aniline
N-(4-phenoxyphenyl)-2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide	[no description available]	low	0	aromatic ether
5-(3,4-dimethoxyphenyl)-3-(2-furanylmethyl)-4-imino-5H-[1]benzopyrano[2,3-d]pyrimidin-8-ol	[no description available]	low	0	aromatic ether
3,3-dimethyl-1,5-dinitro-6-phenoxy-3-azoniabicyclo[3.3.1]non-6-ene	[no description available]	low	0	aromatic ether
fraxin	[no description available]	low	0	aromatic ether; beta-D-glucoside; hydroxycoumarin	anti-inflammatory agent; hepatoprotective agent; plant metabolite
fraxetin	[no description available]	low	0	aromatic ether; hydroxycoumarin	anti-inflammatory agent; antibacterial agent; antimicrobial agent; antioxidant; apoptosis inducer; apoptosis inhibitor; Arabidopsis thaliana metabolite; hepatoprotective agent; hypoglycemic agent
5,6-dehydrokawain	[no description available]	low	0	2-pyranones; aromatic ether
jtk-303	[no description available]	low	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
coniferin	[no description available]	low	0	aromatic ether; cinnamyl alcohol beta-D-glucoside; monosaccharide derivative	plant metabolite
daphnoretin	[no description available]	low	0	aromatic ether; hydroxycoumarin	antineoplastic agent; antiviral agent; metabolite
kavain	[no description available]	low	0	2-pyranones; aromatic ether
methysticin	[no description available]	low	0	2-pyranones; aromatic ether
yangonin	[no description available]	low	0	2-pyranones; aromatic ether
hinokiflavone	[no description available]	low	0	aromatic ether; biflavonoid; hydroxyflavone	antineoplastic agent; metabolite; neuroprotective agent
gentiacaulein	[no description available]	low	0	aromatic ether; polyphenol; xanthones	plant metabolite
gentisin	[no description available]	low	0	aromatic ether; polyphenol; xanthones	plant metabolite
isogentisin	[no description available]	low	0	aromatic ether; polyphenol; xanthones	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
mangostin	[no description available]	low	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
1,8-dihydroxy-3,7-dimethoxyxanthone	[no description available]	low	0	aromatic ether; polyphenol; xanthones	plant metabolite
swerchirin	[no description available]	low	0	aromatic ether; phenols; xanthones	hypoglycemic agent; metabolite
1,2,8-trihydroxy-6-methoxyxanthone	[no description available]	low	0	aromatic ether; polyphenol; xanthones	antioxidant; plant metabolite
wedelolactone	[no description available]	low	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
cyhalothrin	[no description available]	low	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound; organofluorine compound	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
sofalcone	[no description available]	low	0	aromatic ether; chalcones; monocarboxylic acid	anti-ulcer drug; antibacterial agent; gastrointestinal drug; plant metabolite
neticonazole	[no description available]	low	0	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
pibutidine	[no description available]	low	0	aromatic ether; cyclobutenones; olefinic compound; piperidines; primary amino compound; pyridines; secondary amino compound	anti-ulcer drug; H2-receptor antagonist
purmorphamine	[no description available]	low	0	aromatic ether; morpholines; purines; secondary amino compound	osteogenesis regulator; SMO receptor agonist
8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile	[no description available]	low	0	aromatic ether
ro 41-5253	[no description available]	low	0	aromatic ether; benzoic acids; sulfone; thiochromane	apoptosis inducer; retinoic acid receptor alpha antagonist
glycycoumarin	[no description available]	low	0	aromatic ether; coumarins; resorcinols	antispasmodic drug; plant metabolite
isoginkgetin	[no description available]	low	0	aromatic ether; biflavonoid	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; plant metabolite
neoglycyrol	[no description available]	low	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; plant metabolite
rhamnazin	[no description available]	low	0	aromatic ether; dimethoxyflavone; phenols; trihydroxyflavone	antineoplastic agent; plant metabolite
bosutinib	[no description available]	low	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
bw b70c	[no description available]	low	0	aromatic ether; hydroxamic acid; organofluorine compound; ureas	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
lichexanthone	[no description available]	low	0	aromatic ether; phenols; xanthones	plant metabolite
alternariol monomethyl ether	[no description available]	low	0	aromatic ether; benzochromenone	antifungal agent; fungal metabolite; mycotoxin
decussatin	[no description available]	low	0	aromatic ether; phenols; xanthones	plant metabolite
bedaquiline	[no description available]	low	0	aromatic ether; naphthalenes; organobromine compound; quinolines; tertiary alcohol; tertiary amino compound	antitubercular agent; ATP synthase inhibitor
dimethomorph	[no description available]	low	0	aromatic ether; enamide; monochlorobenzenes; morpholine fungicide; tertiary carboxamide
benanomicin b	[no description available]	low	0	aromatic ether; disaccharide derivative; L-alanine derivative; polyketide; polyphenol; pradimicin; secondary alcohol
pradimicin b	[no description available]	low	0	aromatic ether; L-alanine derivative; monosaccharide derivative; polyketide; polyphenol; pradimicin; secondary alcohol
1,7-dihydroxy-4-methoxyxanthone	[no description available]	low	0	aromatic ether; phenols; xanthones	metabolite; plant metabolite
pradimicin a	[no description available]	low	0	aromatic ether; carboxylic acid; disaccharide derivative; L-alanine derivative; p-quinones; polyphenol; pradimicin; secondary alcohol
clodinafop	[no description available]	low	0	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines	EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; phenoxy herbicide
ochnaflavone	[no description available]	low	0	aromatic ether; biflavonoid; hydroxyflavone	anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite
3-(4-fluorophenoxy)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene 1-oxide	[no description available]	low	0	aromatic ether
flavasperone	[no description available]	low	0	aromatic ether; naphtho-gamma-pyrone; phenols	acyl-CoA:cholesterol acyltransferase 2 inhibitor; antiviral agent; Aspergillus metabolite; marine metabolite
4-hydroxycordoin	[no description available]	low	0	aromatic ether; chalcones; polyphenol	anti-inflammatory agent; antibacterial agent; plant metabolite
n-feruloylserotonin	[no description available]	low	0	aromatic ether; cinnamamides; hydroxyindoles; phenols; secondary carboxamide	plant metabolite
tyrphostin ag825	[no description available]	low	0	aromatic ether; benzothiazoles; enamide; nitrile; organic sulfide; phenols; primary carboxamide	epidermal growth factor receptor antagonist
kresoxim-methyl	[no description available]	low	0	aromatic ether; methoxyiminoacetate strobilurin antifungal agent; methyl ester; oxime O-ether	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
5-methoxy-3,6-diphenyl-1,2,4-triazine	[no description available]	low	0	aromatic ether
pyrachlostrobin	[no description available]	low	0	aromatic ether; carbamate ester; carbanilate fungicide; methoxycarbanilate strobilurin antifungal agent; monochlorobenzenes; pyrazoles	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
piericidin a	[no description available]	low	0	aromatic ether; methylpyridines; monohydroxypyridine; secondary allylic alcohol	antimicrobial agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor; mitochondrial respiratory-chain inhibitor
metrafenone	[no description available]	low	0	aromatic ether; aryl phenyl ketone fungicide; benzophenones; organobromine compound	antifungal agrochemical
2-(4-fluoro-3-(trifluoromethyl)phenoxy)-n-(phenylmethyl)butanamide	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; monocarboxylic acid amide; monofluorobenzenes
b 43	[no description available]	low	0	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
5-(4-phenylbutoxy)psoralen	[no description available]	low	0	aromatic ether; benzenes; psoralens	geroprotector; immunosuppressive agent; potassium channel blocker
5-ia-85380	[no description available]	low	0	aromatic ether
yunaconitine	[no description available]	low	0	acetate ester; aromatic ether; benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound	antifeedant; human urinary metabolite; phytotoxin; plant metabolite; xenobiotic
ru 58668	[no description available]	low	0	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; organofluorine compound; sulfone	anti-estrogen; antineoplastic agent; estrogen receptor antagonist
altenusin	[no description available]	low	0	aromatic ether; carboxybiphenyl; catechols; hydroxybiphenyls; polyphenol	antifungal agent; fungal metabolite
gw 501516	[no description available]	low	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
bay 58-2667	[no description available]	low	0	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent
camostat	[no description available]	low	0	aromatic ether; phenols
lenvatinib	[no description available]	low	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
nsc 716970	[no description available]	low	0	aromatic amine; aromatic ether; indolecarboxamide; organochlorine compound	antineoplastic agent
lobeglitazone	[no description available]	low	0	aromatic ether
noviflumuron	[no description available]	low	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; organofluorine compound
etomoxir	[no description available]	low	0	aromatic ether
fr 148083	[no description available]	low	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
9-methoxycanthin-6-one	[no description available]	low	0	aromatic ether; indole alkaloid; organic heterotetracyclic compound	antineoplastic agent; antiplasmodial drug; metabolite
sb 3ct compound	[no description available]	low	0	aromatic ether
varespladib methyl	[no description available]	low	0	aromatic ether; benzenes; indoles; methyl ester; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor; prodrug
dapagliflozin	[no description available]	low	0	aromatic ether; C-glycosyl compound; monochlorobenzenes	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
naveglitazar	[no description available]	low	0	aromatic ether
tivozanib	[no description available]	low	0	aromatic ether
zm 447439	[no description available]	low	0	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor
ustiloxin b	[no description available]	low	0	aromatic ether; heterodetic cyclic peptide; macrocycle; phenols; secondary alcohol; secondary carboxamide; sulfoxide	Aspergillus metabolite; microtubule-destabilising agent; mycotoxin
hypothemycin	[no description available]	low	0	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite
tryprostatin a	[no description available]	low	0	aromatic ether; dipeptide; indole alkaloid; indoles; pyrrolopyrazine	breast cancer resistance protein inhibitor
cediranib	[no description available]	low	0	aromatic ether
3-iodothyronamine	[no description available]	low	0	aromatic ether
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	[no description available]	low	0	aromatic ether; hydrochloride; methoxybenzenes; tertiary amino compound	antipsychotic agent; receptor modulator
rubraxanthone	[no description available]	low	0	aromatic ether; polyphenol; xanthones	antibacterial agent; antineoplastic agent; metabolite
7,8-Dihydroyangonin	[no description available]	low	0	2-pyranones; aromatic ether
sch 51344	[no description available]	low	0	aromatic amine; aromatic ether; primary alcohol; pyrazoloquinoline; secondary amino compound	antineoplastic agent
ancistroealaine a	[no description available]	low	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes	antileishmanial agent; antiplasmodial drug; metabolite; trypanocidal drug
pimavanserin	[no description available]	low	0	aromatic ether; monofluorobenzenes; piperidines; tertiary amino compound; ureas	5-hydroxytryptamine 2A receptor inverse agonist; antipsychotic agent; serotonergic antagonist
tolfenpyrad	[no description available]	low	0	aromatic amide; aromatic ether; organochlorine compound; pyrazole insecticide	agrochemical; antifungal agent; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor
SIS3 free base	[no description available]	low	0	aromatic ether; enamide; isoquinolines; monocarboxylic acid amide; pyrrolopyridine; tertiary carboxamide	Smad3 inhibitor
apixaban	[no description available]	low	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
bibw 2992	[no description available]	low	0	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
dihydrokavain	[no description available]	low	0	2-pyranones; aromatic ether
troglitazone sulfate	[no description available]	low	0	aromatic ether; thiazolidinone
arisugacin	[no description available]	low	0	aromatic ether; delta-lactone; enone; organic heterotetracyclic compound; tertiary alcohol	antimicrobial agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite; Penicillium metabolite
saracatinib	[no description available]	low	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
fonsecinone a	[no description available]	low	0	aromatic ether; aromatic ketone; biaryl; cyclic ketone; naphtho-gamma-pyrone; polyphenol	antibacterial agent; Aspergillus metabolite
crenolanib	[no description available]	low	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
aiphanol	[no description available]	low	0	aromatic ether; benzodioxine; lignan; stilbenoid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
nigerloxin	[no description available]	low	0	aromatic ether; benzamides; benzoic acids; phenols; styrenes	antioxidant; Aspergillus metabolite; EC 1.1.1.21 (aldehyde reductase) inhibitor; lipoxygenase inhibitor; radical scavenger
msdc-0160	[no description available]	low	0	aromatic ether
dihydroxanthohumol	[no description available]	low	0	aromatic ether; dihydrochalcones; polyphenol	EC 1.14.13.39 (nitric oxide synthase) inhibitor; metabolite
PB28	[no description available]	low	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
7-phloroeckol	[no description available]	low	0	aromatic ether; phlorotannin	antioxidant; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; metabolite
3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside	[no description available]	low	0	aromatic ether; benzyl alcohols; beta-D-glucoside; monosaccharide derivative; primary alcohol	antineoplastic agent; metabolite
PDGF receptor tyrosine kinase inhibitor III	[no description available]	low	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
fluoxastrobin	[no description available]	low	0	aromatic ether; dioxazine; monochlorobenzenes; organofluorine compound; oxime O-ether; pyrimidines; strobilurin antifungal agent	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor
flumorph	[no description available]	low	0	aromatic ether; enamide; morpholines; organofluorine compound; tertiary carboxamide
regorafenib	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
erastin	[no description available]	low	0	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
brivanib	[no description available]	low	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
fg-4592	[no description available]	low	0	aromatic ether; isoquinolines; N-acylglycine	EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
picoxystrobin	[no description available]	low	0	aromatic ether; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; organofluorine compound; pyridines	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor
cenicriviroc	[no description available]	low	0	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist
mandipropamid	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; monochlorobenzenes; terminal acetylenic compound
glyceryl ferulate	[no description available]	low	0	1-monoglyceride; aromatic ether; enoate ester; phenols	antioxidant; plant metabolite; ultraviolet filter
ki 8751	[no description available]	low	0	aromatic ether
ceratamine a	[no description available]	low	0	alkaloid; aromatic ether; cyclic ketone; organic heterobicyclic compound; organobromine compound; secondary amino compound; tertiary amine	antimitotic; metabolite
azd 8931	[no description available]	low	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
bay94 9172	[no description available]	low	0	(18)F radiopharmaceutical; aromatic ether; polyether; secondary amino compound; stilbenoid; substituted aniline	radioactive imaging agent
olodaterol	[no description available]	low	0	aromatic ether; benzoxazine; phenols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
dorsomorphin	[no description available]	low	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
cj-042794	[no description available]	low	0	aromatic ether
hu 308	[no description available]	low	0	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist
ki11502	[no description available]	low	0	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
apremilast	[no description available]	low	0	aromatic ether; N-acetylarylamine; phthalimides; sulfone	non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
PF-00835231	[no description available]	low	0	aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	[no description available]	low	0	aminopyridine; aromatic ether; dichlorobenzene; organofluorine compound; pyrazolylpiperidine; racemate	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
chir-265	[no description available]	low	0	aromatic ether
aminocandin	[no description available]	low	0	aromatic ether; echinocandin; homodetic cyclic peptide	antiinfective agent
zk 756326	[no description available]	low	0	aromatic ether
bay 60-6583	[no description available]	low	0	aminopyridine; aromatic ether; aryl sulfide; cyanopyridine; cyclopropanes; monocarboxylic acid amide	adenosine A2B receptor agonist; anti-inflammatory agent; cardioprotective agent
empagliflozin	[no description available]	low	0	aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
4-[5-(4-ethoxyphenyl)-3-isoxazolyl]-N-[(4-methylphenyl)methyl]butanamide	[no description available]	low	0	aromatic ether
bgt226	[no description available]	low	0	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
n-desmethylrosiglitazone	[no description available]	low	0	aromatic ether
4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide	[no description available]	low	0	aromatic ether
verruculogen	[no description available]	low	0	aromatic ether; diol; indole alkaloid; organic heterohexacyclic compound; organic peroxide	Aspergillus metabolite; GABA modulator; mycotoxin; Penicillium metabolite; potassium channel blocker
1-O-feruloyl-beta-D-glucose	[no description available]	low	0	aromatic ether; beta-D-glucoside; cinnamate ester; phenols	antioxidant; plant metabolite
2,2',4,5'-tetrabromodiphenyl ether	[no description available]	low	0	aromatic ether; organobromine compound
hexabromodiphenyl ether 154	[no description available]	low	0	aromatic ether; organobromine compound
bde 183	[no description available]	low	0	aromatic ether; organobromine compound
l-798106	[no description available]	low	0	aromatic ether; bromobenzenes; N-sulfonylcarboxamide	prostaglandin receptor antagonist
aflatoxin m1	[no description available]	low	0	aflatoxin; aromatic ether; aromatic ketone; tertiary alcohol	Aspergillus metabolite; human xenobiotic metabolite; mammalian metabolite
macitentan	[no description available]	low	0	aromatic ether; organobromine compound; pyrimidines; ring assembly; sulfamides	antihypertensive agent; endothelin receptor antagonist; orphan drug
CDN1163	[no description available]	low	0	aromatic ether; quinolines; secondary carboxamide	SERCA activator
e 7050	[no description available]	low	0	aromatic ether
N-[(5-chloro-2-thiophenyl)methyl]-5-[(2,6-difluorophenoxy)methyl]-3-isoxazolecarboxamide	[no description available]	low	0	aromatic ether
dafadine C	[no description available]	low	0	aromatic amide; aromatic ether; difluorobenzene; isoxazoles; N-acylpiperidine; pyridines	P450 inhibitor
dafadine B	[no description available]	low	0	aromatic amide; aromatic ether; isoxazoles; monochlorobenzenes; monofluorobenzenes; N-acylpiperidine; pyridines	P450 inhibitor
3-[5-(5-methyl-2-thiophenyl)-1,3,4-oxadiazol-2-yl]-N-[2-(3-pyridinyloxy)propyl]propanamide	[no description available]	low	0	aromatic ether
violaceol II	[no description available]	low	0	aromatic ether; catechols; resorcinols	mycotoxin
pamapimod	[no description available]	low	0	aromatic amine; aromatic ether; difluorobenzene; diol; primary alcohol; pyridopyrimidine; secondary amino compound	antirheumatic drug; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
gsk690693	[no description available]	low	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024	[no description available]	low	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
uk 453,061	[no description available]	low	0	aromatic ether
8-{1-[4-(dimethylamino)phenyl]-3-(pyrrolidin-1-yl)propyl}-5,7-dimethoxy-4-pentyl-2H-chromen-2-one	[no description available]	low	0	aromatic ether; coumarins; pyrrolidines; tertiary amino compound
zm323881	[no description available]	low	0	aromatic ether; benzyl ether; fluorophenol; halophenol; monofluorobenzenes; organic cation; quinazolines; secondary amino compound; substituted aniline	vascular endothelial growth factor receptor antagonist
compound w	[no description available]	low	0	aromatic ether
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	aromatic ether
interiotherin b	[no description available]	low	0	aromatic ether; fatty acid ester; lignan; organic heteropentacyclic compound; oxacycle	anti-HIV agent; metabolite
5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one	[no description available]	low	0	aromatic ether; homoisoflavonoid; polyphenol	angiogenesis modulating agent; plant metabolite
ph 797804	[no description available]	low	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
diorcinol	[no description available]	low	0	aromatic ether; phenols	fungal metabolite; marine metabolite; metabolite
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	aromatic ether
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	aromatic ether
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	aromatic ether
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	aromatic ether
mk 5108	[no description available]	low	0	aromatic ether
lde225	[no description available]	low	0	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
1-azepanyl-[5-[(4-chloro-3,5-dimethylphenoxy)methyl]-3-isoxazolyl]methanone	[no description available]	low	0	aromatic ether
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine	[no description available]	low	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines	geroprotector; P450 inhibitor
dafadine D	[no description available]	low	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; organofluorine compound; pyridines	P450 inhibitor
1-[(1-ethyl-3-methyl-4-pyrazolyl)methyl]-N-[4-(2-fluorophenoxy)phenyl]-4-piperidinecarboxamide	[no description available]	low	0	aromatic ether
dafadine O	[no description available]	low	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines; ring assembly	P450 inhibitor
5-[(3,4-dimethylphenoxy)methyl]-N-methyl-N-(4-oxanylmethyl)-3-isoxazolecarboxamide	[no description available]	low	0	aromatic ether
pci 32765	[no description available]	low	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
florbetapir f 18	[no description available]	low	0	(18)F radiopharmaceutical; aromatic ether; organofluorine compound; pyridines; substituted aniline	radioactive imaging agent
AMG-208	[no description available]	low	0	aromatic ether; quinolines; triazolopyridazine	antineoplastic agent; c-Met tyrosine kinase inhibitor
6-methoxyspirotryprostatin b	[no description available]	low	0	aromatic ether; azaspiro compound; indole alkaloid; indolones	antineoplastic agent; Aspergillus metabolite
lucitanib	[no description available]	low	0	aromatic ether; cyclopropanes; naphthalenecarboxamide; primary amino compound; quinolines	antineoplastic agent; fibroblast growth factor receptor antagonist; vascular endothelial growth factor receptor antagonist
act-132577	[no description available]	low	0	aromatic ether; organobromine compound; pyrimidines; sulfamides	antihypertensive agent; drug metabolite; endothelin receptor antagonist; xenobiotic metabolite
cabozantinib	[no description available]	low	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
poziotinib	[no description available]	low	0	acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist
gsk 2126458	[no description available]	low	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
gsk 1363089	[no description available]	low	0	aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea	[no description available]	low	0	aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea	[no description available]	low	0	aromatic ether
3-cyclohexyl-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	aromatic ether
3-cyclohexyl-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	aromatic ether
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide	[no description available]	low	0	aromatic ether
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea	[no description available]	low	0	aromatic ether
monepantel	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; aryl sulfide; nitrile; secondary carboxamide	anthelminthic drug; nematicide
an2728	[no description available]	low	0	aromatic ether; benzoxaborole; nitrile	antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
grazoprevir	[no description available]	low	0	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent
hordatine a	[no description available]	low	0	aromatic ether; benzofurans; dicarboxylic acid diamide; guanidines; phenols	adrenergic antagonist; metabolite
5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)-3-pyridazinone	[no description available]	low	0	aromatic ether
tak-632	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor
lrrk2-in1	[no description available]	low	0	aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
quinolobactin	[no description available]	low	0	aromatic ether; monohydroxyquinoline; phenols; quinolinemonocarboxylic acid	bacterial metabolite; siderophore
AZD1979	[no description available]	low	0	aromatic ether; azaspiro compound; carboxamide; N-acylazetidine; oxadiazole; oxaspiro compound; oxetanes	melanin-concentrating hormone receptor antagonist
ML240	[no description available]	low	0	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent
aripiprazole lauroxil	[no description available]	low	0	aromatic ether; delta-lactam; dichlorobenzene; dodecanoate ester; N-alkylpiperazine; N-arylpiperazine; quinolone	H1-receptor antagonist; prodrug; second generation antipsychotic; serotonergic agonist
abt-199	[no description available]	low	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
xl765	[no description available]	low	0	aromatic amine; aromatic ether; benzamides; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
DMH1	[no description available]	low	0	aromatic ether; pyrazolopyrimidine; quinolines	antineoplastic agent; bone morphogenetic protein receptor antagonist; protein kinase inhibitor
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	[no description available]	low	0	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
pf 4800567	[no description available]	low	0	aromatic ether; monochlorobenzenes; oxanes; pyrazolopyrimidine	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
propenylphosphonic acid	[no description available]	low	0	aromatic ether
abt-333	[no description available]	low	0	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor
naloxegol	[no description available]	low	0	aromatic ether; organic heteropentacyclic compound; phenols; polyether; tertiary alcohol	cathartic; mu-opioid receptor antagonist
ceritinib	[no description available]	low	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
MK-8353	[no description available]	low	0	aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
HG-10-102-01	[no description available]	low	0	aminopyrimidine; aromatic ether; monocarboxylic acid amide; morpholines; organochlorine compound; secondary amino compound	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
N-[(5-methyl-2-furanyl)methylideneamino]-2-phenoxybenzamide	[no description available]	low	0	aromatic ether
saroglitazar	[no description available]	low	0	aromatic ether; methyl sulfide; monocarboxylic acid; pyrroles	hypoglycemic agent; PPARalpha agonist; PPARgamma agonist
fertaric acid	[no description available]	low	0	aromatic ether; cinnamate ester; dicarboxylic acid; phenols; tetraric acid derivative
2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; tertiary alcohol; triazoles
pf-06463922	[no description available]	low	0	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
DDR1-IN-1	[no description available]	low	0	(trifluoromethyl)benzenes; aromatic ether; benzamides; N-alkylpiperazine; oxindoles; secondary carboxamide	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ldc4297	[no description available]	low	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
MLI-2	[no description available]	low	0	aromatic ether; cyclopropanes; indazoles; morpholines; pyrimidines; tertiary amino compound	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ap20187	[no description available]	low	0	aromatic ether; carboxylic ester; N-acylpiperidine; tertiary amino compound	ligand
biliatresone	[no description available]	low	0	aromatic ether; aromatic ketone; benzodioxoles; enone; phenols	plant metabolite; toxin
tak 491	[no description available]	low	0	1,2,4-oxadiazole; aromatic ether; benzimidazoles; carboxylic ester; cyclic carbonate ester; dioxolane	angiotensin receptor antagonist; antihypertensive agent; prodrug
azilsartan	[no description available]	low	0	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent
hydrazinocurcumin	[no description available]	low	0	aromatic ether; olefinic compound; polyphenol; pyrazoles	angiogenesis modulating agent; antineoplastic agent; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
mirodenafil	[no description available]	low	0	aromatic ether; N-alkylpiperazine; primary alcohol; pyrrolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
cerulomycin	[no description available]	low	0	aldoxime; aromatic ether; bipyridines; pyridine alkaloid	antineoplastic agent; bacterial metabolite; marine metabolite
undecylprodigiosin	[no description available]	low	0	alkaloid; aromatic ether; tripyrrole	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; biological pigment; immunosuppressive agent; radiosensitizing agent
sb-590885	[no description available]	low	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
2-[[4-(trifluoromethoxy)phenyl]methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one	[no description available]	low	0	aromatic ether
PF-07304814	[no description available]	low	0	aromatic ether; indolecarboxamide; L-leucine derivative; phosphate monoester; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; prodrug

Article	Year
Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. British journal of pharmacology, Volume: 127, Issue: 6	1999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain research, Aug-18, Volume: 1285	2009
Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat. Cardiovascular drugs and therapy, Volume: 6, Issue: 5	1992
A comparison of the effects of acute versus chronic administration of phenoxybenzamine on pressor responses elicited by the selective alpha 1-adrenoceptor agonist cirazoline in the pithed rat preparation. Canadian journal of physiology and pharmacology, Volume: 70, Issue: 6	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Impaired alpha1-adrenergic responses in aged rat hearts. Fundamental & clinical pharmacology, Volume: 19, Issue: 3	2005
Pressor responses to the alpha 1-adrenoceptor agonist cirazoline: effects of captopril, phenoxybenzamine and nifedipine. European journal of pharmacology, Jan-04, Volume: 251, Issue: 1	1994
Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. The Journal of pharmacology and experimental therapeutics, Volume: 227, Issue: 2	1983
Blockade and postjunctional vascular alpha 1- and alpha 2-adrenoceptors in pithed rat by the enantiomers of WB-4101. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 322, Issue: 2	1983
Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil. Circulation research, Volume: 52, Issue: 2 Pt 2	1983
Interaction of the enantiomers of 3-0-methyldobutamine, a metabolite of dobutamine, with alpha- and beta-adrenoreceptors in the cardiovascular system of the pithed rat. Journal of autonomic pharmacology, Volume: 4, Issue: 4	1984
Pharmacologic characterization of cirazoline-activated inositol phospholipid hydrolysis in rat brain cortical slices. Canadian journal of physiology and pharmacology, Volume: 66, Issue: 11	1988
Loss of selectivity of so-called selective alpha 1-adrenoceptor agonists after phenoxybenzamine. Naunyn-Schmiedeberg's archives of pharmacology, Volume: 338, Issue: 3	1988
Interaction of calmodulin antagonists with alpha-adrenergic responses in pithed rats and in the perfused hindquarters of the rat. European journal of pharmacology, Mar-22, Volume: 148, Issue: 1	1988
In vivo assessment of rat renal alpha adrenoceptors. The Journal of pharmacology and experimental therapeutics, Volume: 241, Issue: 2	1987
Regulation of chicken pineal arylalkylamine-N-acetyl transferase by postsynaptic alpha 2-adrenergic receptors. Life sciences, Nov-24, Volume: 39, Issue: 21	1986
The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality, Volume: 1, Issue: 4	1989
Effect of temperature on alpha 2- and alpha 1-adrenoceptor-mediated responses in the pithed rat and in the rat vena cava. Journal of autonomic pharmacology, Volume: 10, Issue: 5	1990
Involvement of 5-HT1A receptors in blood pressure reduction by 8-OH-DPAT and urapidil in cats. Journal of cardiovascular pharmacology, Volume: 15 Suppl 7	1990
Effects of staurosporine on the pressor responses to alpha-adrenoceptor agonists in pithed rats: a comparison with nifedipine. Pharmacology, Volume: 43, Issue: 3	1991
The interrelationship between the effects of captopril and nifedipine on pressor responses elicited by selective alpha-adrenoceptor agonists in the pithed rat preparation. Journal of cardiovascular pharmacology, Volume: 19, Issue: 4	1992
Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat. Cardiovascular drugs and therapy, Volume: 6, Issue: 5	1992
A comparison of the effects of acute versus chronic administration of phenoxybenzamine on pressor responses elicited by the selective alpha 1-adrenoceptor agonist cirazoline in the pithed rat preparation. Canadian journal of physiology and pharmacology, Volume: 70, Issue: 6	1992
Subtype-selective alpha-1 adrenoceptor alkylation in the rat kidney and its effect on the vascular pressor response. The Journal of pharmacology and experimental therapeutics, Volume: 260, Issue: 2	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

cirazoline

Description

Cross-References

Synonyms (72)

Research Excerpts

Overview

Effects

Actions

Drug Classes (1)

Protein Targets (34)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (95)

Molecular Functions (23)

Ceullar Components (26)

Bioassays (103)

Research

Studies (217)

Study Types

Research Highlights

Safety/Toxicity (1)

Long-term Use (3)

Bioavailability (2)

Dosage (22)

Condition	Relationship Strength	Studies
Absence Seizure	low	1
Absence Seizures	low	1
Ache	low	1
Adenoma, beta-Cell	low	1
Aging	low	3
Alloxan Diabetes	low	5
Ambulation Disorders, Neurologic	low	1
Anemia, Fanconi	low	1
Anesthesia	low	2
Animal Mammary Carcinoma	low	1
Aortic Stenosis	low	1
Aortic Valve Stenosis	low	1
Atonic Absence Seizure	low	1
Atonic Absence Seizures	low	1
Atonic Seizure	low	1
Atonic Seizures	low	1
beta-Cell Tumor	low	1
Blood Pressure, High	low	11
Body Weight	low	1
Cancer of Pancreas	low	1
Cancer of the Pancreas	low	1
Cardiac Hypertrophy	low	1
Cardiomegaly	low	1
Central Hypothyroidism	low	1
Charcot Gait	low	1
Charcot's Gait	low	1
Clonic Seizure	low	1
Clonic Seizures	low	1
Complex Partial Seizure	low	1
Complex Partial Seizures	low	1
Congenital Zika Syndrome	low	1
Congenital Zika Virus Infection	low	1
Contact Dermatitis	low	1
Convulsion	low	1
Convulsion, Non-Epileptic	low	1
Convulsions	low	1
Convulsive Seizure	low	1
Convulsive Seizures	low	1
Decerebrate Posturing	low	18
Decerebrate State	low	18
Decorticate Rigidity	low	18
Decorticate State	low	18
Depression, Endogenous	low	1
Depression, Neurotic	low	1
Depression, Unipolar	low	1
Depressive Disorder	low	1
Depressive Syndrome	low	1
Dermatitis Venenata	low	1
Dermatitis, Contact	low	1
Diabetes Mellitus, Adult-Onset	low	2
Diabetes Mellitus, Experimental	low	5
Diabetes Mellitus, Ketosis-Resistant	low	2
Diabetes Mellitus, Maturity-Onset	low	2
Diabetes Mellitus, Non Insulin Dependent	low	2
Diabetes Mellitus, Non-Insulin-Dependent	low	2
Diabetes Mellitus, Noninsulin Dependent	low	2
Diabetes Mellitus, Noninsulin-Dependent	low	2
Diabetes Mellitus, Slow-Onset	low	2
Diabetes Mellitus, Stable	low	2
Diabetes Mellitus, Type 2	low	2
Diabetes Mellitus, Type II	low	2
Diabetic Angiopathies	low	1
Diabetic Vascular Complications	low	1
Diabetic Vascular Diseases	low	1
Disease Models, Animal	low	4
Duck Gait	low	1
Eczema, Contact	low	1
Encephalitis, Polio	low	1
Enlarged Heart	low	1
Epidemic Acute Poliomyelitis	low	1
Epileptic Seizure	low	1
Epileptic Seizures	low	1
Experimental Diabetes Mellitus	low	5
Fanconi Anemia	low	1
Fanconi Hypoplastic Anemia	low	1
Fanconi Pancytopenia	low	1
Fanconi Panmyelopathy	low	1
Fanconi's Anemia	low	1
Fever, Zika	low	1
Gait Disorder, Sensorimotor	low	1
Gait Disorders, Neurologic	low	1
Gait Dysfunction, Neurologic	low	1
Gait, Athetotic	low	1
Gait, Broadened	low	1
Gait, Drop Foot	low	1
Gait, Festinating	low	1
Gait, Frontal	low	1
Gait, Hemiplegic	low	1
Gait, Hysterical	low	1
Gait, Reeling	low	1
Gait, Rigid	low	1
Gait, Scissors	low	1
Gait, Shuffling	low	1
Gait, Spastic	low	1
Gait, Stumbling	low	1
Gait, Unsteady	low	1
Gait, Widebased	low	1
Generalized Absence Seizure	low	1
Generalized Absence Seizures	low	1
Generalized Tonic-Clonic Seizures	low	1
Goldblatt Syndrome	low	1
Heart Enlargement	low	1
Heart Hypertrophy	low	1
Hypersensitivity, Contact	low	1
Hypertension	low	11
Hypertension, Goldblatt	low	1
Hypertension, Renal	low	1
Hypertension, Renovascular	low	1
Hypothyroidism	low	1
Infantile Paralysis	low	1
Insulinoma	low	1
Insuloma	low	1
Itching	low	1
Jacksonian Seizure	low	1
Locomotion Disorders, Neurologic	low	1
Mammary Carcinoma, Animal	low	1
Mammary Neoplasms	low	1
Mammary Neoplasms, Animal	low	1
Marche a Petit Pas	low	1
Maturity-Onset Diabetes	low	2
Maturity-Onset Diabetes Mellitus	low	2
Melancholia	low	1
Microangiopathy, Diabetic	low	1
MODY	low	2
Muscle Contraction	low	20
Myoclonic Seizure	low	1
Myoclonic Seizures	low	1
Neoplasms, Mammary	low	1
Neoplasms, Pancreatic	low	1
Neurologic Ambulation Disorders	low	1
Neurologic Locomotion Disorders	low	1
Neurosis, Depressive	low	1
NIDDM	low	2
Non-Epileptic Seizure	low	1
Non-Epileptic Seizures	low	1
Nonepileptic Seizure	low	1
Nonepileptic Seizures	low	1
Noninsulin-Dependent Diabetes Mellitus	low	2
Pain	low	1
Pain, Burning	low	1
Pain, Crushing	low	1
Pain, Migratory	low	1
Pain, Radiating	low	1
Pain, Splitting	low	1
Pancreas Cancer	low	1
Pancreas Neoplasms	low	1
Pancreatic Cancer	low	1
Pancreatic Neoplasms	low	1
Partial Seizure	low	1
Partial Seizures	low	1
Petit Mal Convulsion	low	1
Polio	low	1
Polio Encephalitis	low	1
Poliomyelitis	low	1
Poliomyelitis Infection	low	1
Poliomyelitis, Acute	low	1
Poliomyelitis, Nonpoliovirus	low	1
Poliomyelitis, Preparalytic	low	1
Pregnancy	low	4
Primary Hypothyroidism	low	1
Pruritis	low	1
Pruritus	low	1
Rapid Fatigue of Gait	low	1
Rigidity, Decerebrate	low	18
Rigidity, Decorticate	low	18
Secondary Hypothyroidism	low	1
Seizure	low	1
Seizures	low	1
Seizures, Auditory	low	1
Seizures, Clonic	low	1
Seizures, Convulsive	low	1
Seizures, Epileptic	low	1
Seizures, Focal	low	1
Seizures, Generalized	low	1
Seizures, Gustatory	low	1
Seizures, Motor	low	1
Seizures, Olfactory	low	1
Seizures, Sensory	low	1
Seizures, Somatosensory	low	1
Seizures, Tonic	low	1
Seizures, Tonic-Clonic	low	1
Seizures, Vertiginous	low	1
Seizures, Vestibular	low	1
Seizures, Visual	low	1
Sensitivity and Specificity	low	2
Sensitivity, Contact	low	1
Sensorimotor Gait Disorder	low	1
Single Seizure	low	1
Streptozocin Diabetes	low	5
Streptozotocin Diabetes	low	5
Suffering, Physical	low	1
Tachyarrhythmia	low	1
Tachycardia	low	1
Thyroid-Stimulating Hormone Deficiency	low	1
Tonic Clonic Seizure	low	1
Tonic Seizure	low	1
Tonic Seizures	low	1
Tonic-Clonic Seizure	low	1
Tonic-Clonic Seizures	low	1
TSH Deficiency	low	1
Type 2 Diabetes	low	2
Type 2 Diabetes Mellitus	low	2
Unipolar Depression	low	1
Urinary Incontinence, Stress	low	1
Urinary Stress Incontinence	low	1
Zika Fever	low	1
Zika Virus Disease	low	1
Zika Virus Infection	low	1
ZikV Infection	low	1

cirazoline

Description

Cross-References

Synonyms (72)

Research Excerpts

Overview

Effects

Actions

Drug Classes (1)

Protein Targets (34)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (95)

Molecular Functions (23)

Ceullar Components (26)

Bioassays (103)

Research

Studies (217)

Study Types

Related Drugs (994)

Related Conditions (209)

Research Highlights

Safety/Toxicity (1)

Long-term Use (3)

Bioavailability (2)

Dosage (22)